<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="42147"><DrugName>fidaxomicin</DrugName><DrugNamesKey><Name id="43129977">Dafclir</Name><Name id="42951607">Dificid</Name><Name id="42962287">Dificlir</Name><Name id="42891745">fidaxomicin</Name></DrugNamesKey><DrugSynonyms><Name><Value>OP-1118</Value><Types><Type>Metabolite</Type></Types></Name><Name><Value>R-tiacumicin B</Value></Name><Name><Value>OPT-80</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PAR-101</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>fidaxomicin</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>Difimicin</Value></Name><Name><Value>Dificid</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Dificlir</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>fidaxomicin (oral suspension, C difficile infection), Optimer</Value></Name><Name><Value>fidaxomicin (oral suspension, C difficile infection), Cubist Pharmaceuticals</Value></Name><Name><Value>ASP-2819</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Dafclir</Value></Name><Name><Value>873857-62-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29549">Optimer Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="1013295">Astellas Pharma Inc</Company><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Company id="18077">Merck &amp; Co Inc</Company><Company id="14190">AstraZeneca plc</Company><Company id="21697">Cubist Pharmaceuticals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1089119">OBI Pharma Inc</Company><Company id="28968">Par Pharmaceutical Co Inc</Company><Company id="29549">Optimer Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="42147" type="Drug"><TargetEntity id="134139" type="siDrug">Fidaxomicin</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1044298" type="Company"><TargetEntity id="5035525776" type="organizationId">Specialised Therapeutics Australia Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="1089119" type="Company"><TargetEntity id="5000693472" type="organizationId">OBI Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="21697" type="Company"><TargetEntity id="4295906092" type="organizationId">Cubist Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="28968" type="Company"><TargetEntity id="5000049965" type="organizationId">Par Pharmaceutical Companies Inc</TargetEntity></SourceEntity><SourceEntity id="29549" type="Company"><TargetEntity id="4295902183" type="organizationId">Optimer Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="102" type="ciIndication"><TargetEntity id="10012735" type="MEDDRA"></TargetEntity><TargetEntity id="D003967" type="MeSH"></TargetEntity><TargetEntity id="-957779542" type="omicsDisease"></TargetEntity><TargetEntity id="380" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1481" type="ciIndication"><TargetEntity id="10061124" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="995" type="ciIndication"><TargetEntity id="3913" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="416" type="Action"><TargetEntity id="8088" type="Mechanism">Cytochrome P450 (Fungal) Inhibitors</TargetEntity><TargetEntity id="2210" type="Mechanism">Cytochrome P450 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="347" type="Action"><TargetEntity id="3608" type="Mechanism">RNA Polymerase Inhibitors</TargetEntity><TargetEntity id="7076" type="Mechanism">RNA Polymerase (Bacterial) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Clostridium difficile infection - US - Jul-2011</FirstLaunched><FirstLaunched>Diarrhea - US - Jul-2011</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="102">Diarrhea</Indication><Indication id="1481">Enterococcus infection</Indication><Indication id="995">Clostridium difficile infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="347">RNA polymerase inhibitor</Action><Action id="416">Cytochrome P450 reductase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1540">Macrolide antibiotic</Action><Action id="7293">Synergist</Action><Action id="1594">Antibacterial</Action><Action id="1538">Bacterial protein synthesis inhibitor</Action><Action id="439">RNA synthesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="236">Macrolide</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="630">Stereochemistry</Technology><Technology id="66">Antibiotic</Technology><Technology id="743">Granule</Technology><Technology id="751">Film coating</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J1F</Code><Name>MACROLIDES AND SIMILAR TYPES</Name></Ephmra><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-27T10:29:39.000Z</LastModificationDate><ChangeDateLast>2019-06-27T00:00:00.000Z</ChangeDateLast><AddedDate>2002-10-18T15:48:22.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="21697" linkType="Company"&gt;Cubist Pharmaceuticals&lt;/ulink&gt; (now a wholly owned subsidiary of &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt;, and  formerly &lt;ulink linkID="29549" linkType="Company"&gt;Optimer Pharmaceuticals&lt;/ulink&gt;)  and &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas Pharma&lt;/ulink&gt;  have developed  and launched fidaxomicin (OPT-80; PAR-101; ASP-2819; Dificid; Dafclir; Dificlir; previously Difimicin; a mixture of distinct stereoisomers of &lt;ulink linkID="4553" linkType="Drug"&gt;tiacumicin B&lt;/ulink&gt;; structure shown), a tablet-formulated macrolide antibiotic that inhibits bacterial RNA polymerase and  CYP P450 enzymes [&lt;ulink linkID="1491823" linkType="Reference"&gt;1491823&lt;/ulink&gt;], [&lt;ulink linkID="1627968" linkType="Reference"&gt;1627968&lt;/ulink&gt;].  In the US, the drug is indicated in adults for the treatment of Clostridium difficile-associated diarrhea (CDAD)  [&lt;ulink linkID="1195908" linkType="Reference"&gt;1195908&lt;/ulink&gt;]. In Europe, the drug is indicated in adults for the treatment of Clostridium difficile infections (CDI) also known as CDAD [&lt;ulink linkID="1298878" linkType="Reference"&gt;1298878&lt;/ulink&gt;]. In Japan, the drug is indicated for the treatment of C difficile-associated infectious enteritis, including pseudomembranous colitis [&lt;ulink linkID="2050804" linkType="Reference"&gt;2050804&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2011, fidaxomicin was launched in the US for the treatment of CDAD in adults [&lt;ulink linkID="1208229" linkType="Reference"&gt;1208229&lt;/ulink&gt;].  In June 2012, fidaxomicin was launched in Europe for the treatment of adults with C difficile infections [&lt;ulink linkID="1298462" linkType="Reference"&gt;1298462&lt;/ulink&gt;].  In September 2018, the product was launched in Japan  for the treatment treatment of C difficile-associated infectious enteritis, including pseudomembranous colitis [&lt;ulink linkID="2073663" linkType="Reference"&gt;2073663&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Development in other indications is ongoing. The product is also being investigated for the potential treatment of &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt;-resistant enterococcus  (VRE) infection  [&lt;ulink linkID="467209" linkType="reference"&gt;467209&lt;/ulink&gt;]. In March 2010, development was ongoing; at that time, Optimer was deciding whether to proceed with clinical trials for the prevention of VRE in C difficile-infected patients [&lt;ulink linkID="1089904" linkType="Reference"&gt;1089904&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development for the prophylaxis of CDAD was previously ongoing. In June 2011, Optimer was planning to expand the label of the product in the US to include prophylaxis of CDAD [&lt;ulink linkID="1205412" linkType="Reference"&gt;1205412&lt;/ulink&gt;]. In March 2012, Optimer planned to develop fidaxomicin for the prophylaxis of CDAD in high-risk patients, initially in patients undergoing bone marrow transplantation (BMT), and potentially in patients with cancer [&lt;ulink linkID="1273395" linkType="Reference"&gt;1273395&lt;/ulink&gt;]; in July 2012, Optimer planned to develop fidaxomicin for a broad prophylaxis indication for immunosuppressed patients [&lt;ulink linkID="1313325" linkType="Reference"&gt;1313325&lt;/ulink&gt;]. In November 2012, a phase IIIb trial (DEFLECT-1) began to assess the drug for the prophylaxis of CDAD in BMT patients [&lt;ulink linkID="1336492" linkType="Reference"&gt;1336492&lt;/ulink&gt;];    in June 2016, data were reported [&lt;ulink linkID="1773151" linkType="Reference"&gt;1773151&lt;/ulink&gt;]. No further development regarding the drug for the  prophylaxis  of CDAD has since been reported. &lt;/para&gt;&lt;para&gt;Cubist and Astellas are also developing an oral suspension formulation of fidaxomicin for the potential pediatric treatment of CDAD [&lt;ulink linkID="1273395" linkType="Reference"&gt;1273395&lt;/ulink&gt;], [&lt;ulink linkID="1587702" linkType="Reference"&gt;1587702&lt;/ulink&gt;]. In  January 2019, the drug was filed in Europe for CDI in pediatric patients, presumably  for both the film-coated tablet formulation and granules for oral suspension formulation [&lt;ulink linkID="2146687" linkType="Reference"&gt;2146687&lt;/ulink&gt;], [&lt;ulink linkID="2154391" linkType="Reference"&gt;2154391&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In May 2008, the USPTO issued &lt;ulink linkID="PA3567106" linkType="Patent"&gt;US-07378508&lt;/ulink&gt;, which claimed polymorphic crystalline forms of tiacumicin B, including fidaxomicin [&lt;ulink linkID="910332" linkType="Reference"&gt;910332&lt;/ulink&gt;]. In April 2009, Optimer was issued &lt;ulink linkID="PA3339705" linkType="Patent"&gt;US-07507564&lt;/ulink&gt;, equivalent to &lt;ulink linkID="PA2888739" linkType="Patent"&gt;WO-2004014295&lt;/ulink&gt;, which covered steps used in the manufacture of fidaxomicin [&lt;ulink linkID="999747" linkType="Reference"&gt;999747&lt;/ulink&gt;]. By March 2010, the company had filed a number of patent applications [&lt;ulink linkID="1089904" linkType="Reference"&gt;1089904&lt;/ulink&gt;]. In January 2011, &lt;ulink linkID="PA3673012" linkType="Patent"&gt;US-07863249&lt;/ulink&gt; was issued covering additional dosage forms of fidaxomicin [&lt;ulink linkID="1158949" linkType="Reference"&gt;1158949&lt;/ulink&gt;]. In February 2014, fidaxomicin was covered in the US by five issued patents. At that time, 12 US patent applications were pending [&lt;ulink linkID="1273395" linkType="Reference"&gt;1273395&lt;/ulink&gt;]; the five patents were &lt;ulink linkID="PA3339705" linkType="Patent"&gt;US-07507564&lt;/ulink&gt; (expires April 2024), &lt;ulink linkID="PA5481224" linkType="Patent"&gt;US-08586551&lt;/ulink&gt; (expires April 2024), &lt;ulink linkID="PA3704897" linkType="Patent"&gt;US-07906489&lt;/ulink&gt; (expires March 2027), US-07378508 (expires July 2027) and &lt;ulink linkID="PA3673012" linkType="Patent"&gt;US-07863249&lt;/ulink&gt; (expires July 2027) [&lt;ulink linkID="1529582" linkType="Reference"&gt;1529582&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2012, fidaxomicin had been issued 13 foreign patents with 67 patent applications pending worldwide in Australia, Canada, China, Europe, Hong Kong, Israel, Japan South Korea, India and New Zealand, Taiwan, South Africa, Russia, Mexico and Brazil. The issued patents covered specific polymorphic form, methods of treatment and specific manufacturing methods of fidaxomicin, and were to expire in 2027, 2023 and 2025, respectively. The pending patent applications would cover the composition of matter, an additional polymorphic form and pharmaceutical formulations containing certain components if issued, and provide exclusivity from 2023 to 2029 [&lt;ulink linkID="1273395" linkType="Reference"&gt;1273395&lt;/ulink&gt;]. By March 2013, the issued patents were to expire in 2027, 2027 and 2025 [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2011, Optimer planned to expand the US label of fidaxomicin to include prophylaxis of CDAD [&lt;ulink linkID="1205412" linkType="Reference"&gt;1205412&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, Orphan Drug designation was granted by the FDA for the treatment of CDI in children aged 16 years or younger [&lt;ulink linkID="1158609" linkType="Reference"&gt;1158609&lt;/ulink&gt;], [&lt;ulink linkID="1175894" linkType="Reference"&gt;1175894&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2004, fidaxomicin  had been granted Fast Track status for  CDAD by the FDA [&lt;ulink linkID="568699" linkType="Reference"&gt;568699&lt;/ulink&gt;]. In September 2010, a rolling NDA was submitted to the FDA for the treatment and recurrence prevention of CDI [&lt;ulink linkID="1133053" linkType="Reference"&gt;1133053&lt;/ulink&gt;]; in November 2010, the filing was completed [&lt;ulink linkID="1152480" linkType="Reference"&gt;1152480&lt;/ulink&gt;]. In January 2011, the NDA filing was accepted by the FDA and was granted Priority Review status [&lt;ulink linkID="1162863" linkType="Reference"&gt;1162863&lt;/ulink&gt;]. In April 2011, the FDA's Anti-Infective Drugs Advisory Committee recommended approval of fidaxomicin for CDI [&lt;ulink linkID="1181850" linkType="Reference"&gt;1181850&lt;/ulink&gt;]. In May 2011, the FDA approved fidaxomicin for the treatment of CDAD and it was  launched in July 2011  [&lt;ulink linkID="1195665" linkType="Reference"&gt;1195665&lt;/ulink&gt;], [&lt;ulink linkID="1208229" linkType="Reference"&gt;1208229&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In July 2010, Optimer submitted an MAA to the EMA for the treatment of CDI [&lt;ulink linkID="1119727" linkType="Reference"&gt;1119727&lt;/ulink&gt;]; in August 2010, the EMA accepted the MAA for review [&lt;ulink linkID="1125141" linkType="Reference"&gt;1125141&lt;/ulink&gt;]. In September 2011, the EMA's CHMP recommended approval of fidaxomicin for the treatment of adult CDI [&lt;ulink linkID="1225154" linkType="Reference"&gt;1225154&lt;/ulink&gt;], [&lt;ulink linkID="1225202" linkType="Reference"&gt;1225202&lt;/ulink&gt;]. In December 2011,  approval was granted [&lt;ulink linkID="1247655" linkType="Reference"&gt;1247655&lt;/ulink&gt;]; in May 2012, the 		drug was launched in UK  [&lt;ulink linkID="1354560" linkType="Reference"&gt;1354560&lt;/ulink&gt;], [&lt;ulink linkID="1298462" linkType="Reference"&gt;1298462&lt;/ulink&gt;]. In December 2011, the drug was approved in Czech Republic and Iceland [&lt;ulink linkID="1445029" linkType="Reference"&gt;1445029&lt;/ulink&gt;] and  subsequently launched in both the countries [&lt;ulink linkID="1453159" linkType="Reference"&gt;1453159&lt;/ulink&gt;], [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;], [&lt;ulink linkID="1444818" linkType="Reference"&gt;1444818&lt;/ulink&gt;]; and also, the drug was approved in Latvia and Estonia  [&lt;ulink linkID="1455845" linkType="Reference"&gt;1455845&lt;/ulink&gt;], [&lt;ulink linkID="1460145" linkType="Reference"&gt;1460145&lt;/ulink&gt;].    In June 2012, the drug was launched in Portugal [&lt;ulink linkID="1383731" linkType="Reference"&gt;1383731&lt;/ulink&gt;]. By July 2012, fidaxomicin was available in Austria, Sweden, Denmark, Finland, Norway and the Netherlands [&lt;ulink linkID="1313325" linkType="Reference"&gt;1313325&lt;/ulink&gt;].  In November 2012, the drug was launched in France [&lt;ulink linkID="1352724" linkType="Reference"&gt;1352724&lt;/ulink&gt;]. By December 2012, it had been launched in Spain [&lt;ulink linkID="1358233" linkType="Reference"&gt;1358233&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In July 2017, Astellas submitted an application for marketing approval of fidaxomicin for the treatment of infectious enteritis caused by C difficile [&lt;ulink linkID="1949611" linkType="Reference"&gt;1949611&lt;/ulink&gt;]; in July 2018, the product was approved in Japan for the treatment of C difficile-associated infectious enteritis, including pseudomembranous colitis [&lt;ulink linkID="2050804" linkType="Reference"&gt;2050804&lt;/ulink&gt;]; in September 2018, the product was launched in Japan [&lt;ulink linkID="2073663" linkType="Reference"&gt;2073663&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In November 2011, Optimer filed an NDS for the drug in Canada for CDAD. Health Canada awarded the filing Priority Review [&lt;ulink linkID="1236034" linkType="Reference"&gt;1236034&lt;/ulink&gt;]. In July 2012, fidaxomicin was approved and launched in Canada for the treatment of CDI [&lt;ulink linkID="1306423" linkType="Reference"&gt;1306423&lt;/ulink&gt;], [&lt;ulink linkID="1306495" linkType="Reference"&gt;1306495&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Caribbean&lt;/subtitle&gt;By March 2013, the drug had been approved in Caribbean, where it would be marketed by licensee &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;   [&lt;ulink linkID="1346318" linkType="Reference"&gt;1346318&lt;/ulink&gt;], [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By March 2013, the drug had been approved in Mexico, where it would be marketed by licensee AstraZeneca   [&lt;ulink linkID="1346318" linkType="Reference"&gt;1346318&lt;/ulink&gt;], [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2013, the drug had been approved in Latin America, where it would be marketed by licensee AstraZeneca   [&lt;ulink linkID="1346318" linkType="Reference"&gt;1346318&lt;/ulink&gt;],  [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2013, the drug had been approved in Brazil, where it would be marketed by licensee AstraZeneca   [&lt;ulink linkID="1346318" linkType="Reference"&gt;1346318&lt;/ulink&gt;],   [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In June 2011, the drug was granted Priority Review status in Taiwan. In July 2012, an NDA was approved for the drug in Taiwan for CDAD; at that time,  &lt;ulink linkID="1089119" linkType="Company"&gt;OBI Pharma&lt;/ulink&gt; (formerly Optimer Biotechnology; previously a subsidiary of Optimer Pharmaceuticals) expected to launch the drug in Taiwan in August 2012 [&lt;ulink linkID="1493254" linkType="Reference"&gt;1493254&lt;/ulink&gt;]. By October 2015, the drug had been launched by OBI in Taiwan. At that time, commercialization of the product was transferred to Merck in Taiwan [&lt;ulink linkID="1699989" linkType="Reference"&gt;1699989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2012, fidaxomicin had been filed for approval in Australia by licensee &lt;ulink linkID="1044298" linkType="Company"&gt;Specialised Therapeutics Australia&lt;/ulink&gt; [&lt;ulink linkID="1302254" linkType="Reference"&gt;1302254&lt;/ulink&gt;]. By April 2013, fidaxomicin was available in Australia under the Special Access Scheme. In April 2013, fidaxomicin was approved in Australia. In May, the drug was made available there  [&lt;ulink linkID="1410754" linkType="Reference"&gt;1410754&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2013, the drug had been approved in New Zealand [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;In April 2017, data from a randomized, controlled, open-label, multicenter phase IIIb/IV  trial (EXTEND; &lt;ulink linkID="225496" linkType="Protocol"&gt;NCT02254967&lt;/ulink&gt;) of extended-pulsed fidaxomicin (EPFX) versus vancomycin were presented at the 27th ECCMID in Vienna, Austria. Patients with C difficile infection aged &amp;gt;/= 60 years (n = 364) were randomized (1:1) to receive fidaxomicin tablets (200 mg po) bid on days 1 to 5 then qod on days 7 to 25 or vancomycin capsules (125 mg po) qid on days 1 to 10. At day 30 after end of treatment, 70.1% of patients in the EPFX arm had achieved a sustained clinical cure (SCC) compared with 59.2% in the vancomycin arm (p = 0.030). Significant differences in SCC acheivement between the treatment groups were also reported at days 40, 55 and 90. EPFX treatment also  significantly lowered recurrence rates at days 40, 55 and 90 (1.7, 4 and 6.2%), compared with vancomycin (16.8, 17.9 and 19%;  p &amp;lt; 0.001). Treatment-emergent adverse event (TEAE) rates were similar across both groups at 66.9 and 70.7% for EPFX and vancomycin, respectively, with TEAEs related to drug reported in 7.7 and 5%, respectively. Severe and serious TEAEs were reported in 24.3 and 37.6% of EPFX-treated patients and in 30.9 and 43.1% of vancomycin-treated patients, respectively [&lt;ulink linkID="1920538" linkType="Reference"&gt;1920538&lt;/ulink&gt;], [&lt;ulink linkID="1920957" linkType="Reference"&gt;1920957&lt;/ulink&gt;]. In October 2017, further sub-group analysis data were presented at the 2017 IDWeek in San Diego, CA. When compared to vanomycin, extended-pulsed fidaxomicin showed higher rates of SCC at 30 days after end of treatment (primary endpoint) in severe (ratio: 11.2, p = 0.200) and non severe CDI (ratio: 10.3, p = 0.094) patients; in patients with (ratio: 11.9, p = 0.302) or without cancer (ratio: 10.7, p = 0.056); and in patients with zero (ratio: 7.4, p = 0.191), one (ratio: 17.1, p = 0.201) and two previous incidence of CDI episodes (ratio:40.0, p = 0.068) [&lt;ulink linkID="1968126" linkType="Reference"&gt;1968126&lt;/ulink&gt;]. In October 2018, further data were presented at the 2018 IDWeek in San Francisco, CA. Incidence of CDI recurrence was significantly lower at days 40, 55 and 90 in the extended-pulsed fidaxomicin arm than in the standard vancomycin arm (difference = -15.1, -13.9 and -12.8, respectively, p &amp;lt; 0.001 for all). In modified full analysis set (n = 356), 45 patients had a recurrent episode of CDI; the most common recurrence category was reinfection (44.4%)  [&lt;ulink linkID="2078150" linkType="Reference"&gt;2078150&lt;/ulink&gt;]. At the same conference, further data were presented. It was observed that majority of samples that tested positive for C difficile by ELISA also showed positive results for C difficile by BioFire (97.8%). Based on BioFire, majority of patients in both treatment groups tested positive for C difficile only at screening (67.9 and 72.8% for EPFX and vancomycin, respectively). In addition, majority of patients reporting CDI recurrence tested positive for C difficile only (77.8 and 62.5%, respectively)   [&lt;ulink linkID="2078196" linkType="Reference"&gt;2078196&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2017, clinical data from an open-label, multicenter, single-arm PROFILE study were presented at the 12th Congress of ECCO IBD in Barcelona, Spain. Patients (n = 24; 14 with Crohn's disease (CD) and 10 with ulcerative colitis (UC)) received fidaxomicin (200 mg, bid) for 10 days. The AUC, Cmax and Tmax on day 1, 5 and 10 was 77.7, 155.6 and 129.1 ng/h/ml, 14.6, 20.3 and 16.3 ng/ml, and 2.8, 1.3 and 2.2 h, respectively, while the C(trough) on days 5 and 10 was 6.2 and 4.4 ng/ml, respectively. No deaths were reported [&lt;ulink linkID="1903312" linkType="Reference"&gt;1903312&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In July 2015, an open label, single group assigned phase IV trial (&lt;ulink linkID="229259" linkType="Protocol"&gt;NCT02437591&lt;/ulink&gt;; 2819-MA-1003, 2014-003002-32) was initiated in Germany and Greece to evaluate the pharmacokinetics of fidaxomicin in inflammatory bowel disease patients (expected n = 40) with clostridium difficile infection. At that time, the trial was expected to complete in October 2017 [&lt;ulink linkID="1678155" linkType="Reference"&gt;1678155&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, Cubist stated that as part of US approval, the FDA had required a microbiological surveillance program to identify the potential for decreased susceptibility of C difficile to fidaxomicin, which was presumed to be ongoing at that time [&lt;ulink linkID="1529582" linkType="Reference"&gt;1529582&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2013, a post-marketing phase III trial for CDAD in pediatric patients was underway in the US and Europe [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a study assessing the drug in CDAD patients who had experienced multiple recurrences was to be initiated in 2H13 [&lt;ulink linkID="1312246" linkType="Reference"&gt;1312246&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2012, phase II trials had begun for pediatric CDAD [&lt;ulink linkID="1273395" linkType="Reference"&gt;1273395&lt;/ulink&gt;]. The phase IIa open-label, uncontrolled, safety, tolerability and pharmacokinetic trial (&lt;ulink linkID="87156" linkType="Protocol"&gt;NCT01591863&lt;/ulink&gt;; OPT-80-206) would enroll 32 pediatric CDI patients aged from 6 months to 18 years [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;].  In June 2012, the trial was initiated in pediatric patients to assess the safety, tolerability and pharmacokinetics of fidaxomicin tablets and at that time, the trial was expected to complete in January 2014 [&lt;ulink linkID="1468786" linkType="Reference"&gt;1468786&lt;/ulink&gt;]. In March 2014, the study was completed [&lt;ulink linkID="1468786" linkType="Reference"&gt;1468786&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, data from a an open-label, single-arm phase I trial in children (n = 40) with CDAD were presented at the 2014 IDWeek in Philadelphia, PA. The overall clinical response rate was 92% across all age groups, with complete (100%) clinical response rates obtained in the 6 to &amp;lt; 12  and 12 to &amp;lt; 18 years groups. The recurrence rate was 29% across all age groups and a sustained clinical response was reported in 66% of all patients. Adverse events and dose-related adverse events were reported in 74 and 13% of children; however, most adverse events were mild. Serious and severe adverse events were reported in 24 and 7.9% of children, respectively [&lt;ulink linkID="1598804" linkType="Reference"&gt;1598804&lt;/ulink&gt;], [&lt;ulink linkID="1600613" linkType="Reference"&gt;1600613&lt;/ulink&gt;], [&lt;ulink linkID="1601652" linkType="Reference"&gt;1601652&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Tablet formulation&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In November 2012, the phase IIIb, randomized, double-blind, 340-patient trial  (&lt;ulink linkID="92240" linkType="Protocol"&gt;NCT01691248&lt;/ulink&gt;; DEFLECT-1) began to assess the  prophylaxis of CDAD in  BMT patients undergoing hematopoietic stem cell transplant (HSCT) [&lt;ulink linkID="1336492" linkType="Reference"&gt;1336492&lt;/ulink&gt;], [&lt;ulink linkID="1393712" linkType="Reference"&gt;1393712&lt;/ulink&gt;], [&lt;ulink linkID="2115056" linkType="Reference"&gt;2115056&lt;/ulink&gt;]. In January 2014, data from an unblinded interim analysis conducted by the DSMB were  expected later in 2Q14,which would be used to plan the next step for the trial  [&lt;ulink linkID="1518567" linkType="Reference"&gt;1518567&lt;/ulink&gt;]. In April 2015, the trial conducted in 611 patients was completed [&lt;ulink linkID="1703989" linkType="Reference"&gt;1703989&lt;/ulink&gt;], [&lt;ulink linkID="2115056" linkType="Reference"&gt;2115056&lt;/ulink&gt;]. In December 2015, further clinical data were presented at the 57th ASH Annual Meeting and Exposition in Orlando, FL. Incidence of C. difficile associated diarrhea (CDAD) through 30 days after the end of treatment (primary endpoint) with fidaxomicin versus placebo was 28.6 versus 30.8% (p = 0.2778). Toxin positive CDAD incidence was almost twice in allo HSCT compared to auto HSCT recepients (14.6 versus 8%). Toxin positive CDAD incidence was almost twice in allo HSCT versus auto HSCT recipients. Prophylactic fidaxomicin reduced the incidence of confirmed CDAC in both auto and allo HSCT recipients [&lt;ulink linkID="1718802" linkType="Reference"&gt;1718802&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 2016 ASM Microbe Conference in Boston, MA. In fidaxomicin and placebo arms, 13.2 and 12.3% of subjects were colonized with vancomycin-resistant Enterococcus (VRE) colonization at screeing, respectively. Incidence of VRE colonization in fidaxomicin and placebo arm at follow-up period was 15.6 and 26.4%, respectively. Proportion of subjects negative at screening but positive at end of treatment in placebo and fidaxomicin arm were 17.7 and 8.4%, respectively [&lt;ulink linkID="1773151" linkType="Reference"&gt;1773151&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, the drug was listed as being in phase III development in Japan for enteritis caused by Clostridium difficile [&lt;ulink linkID="1521014" linkType="Reference"&gt;1521014&lt;/ulink&gt;]. In October 2016, this was still the case [&lt;ulink linkID="1869233" linkType="Reference"&gt;1869233&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, clinical data from two randomized, double-blind, multicenter phase III trials were presented at IDWeek 2013 in San Francisco, CA. Patients received fidaxomicin (200 mg bid; arm1) or vancomycin (125 mg qid; arm2) for 10 days. Of 1164 patients enrolled, 990 experienced clinical cure (primary endpoint). In arms 1 and 2, 14 and 26% of patients experienced recurrence.  Up to 28 days post-therapy, fidaxomicin demonstrated 2.5- and 3-fold lower cumulative risks of relapse and reinfection when compared with vancomycin [&lt;ulink linkID="1482070" linkType="Reference"&gt;1482070&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, data from a 55 patient Swedish study in C difficile-associated diarrhea patients were presented at the 22nd ECCMID in London, UK. Fidaxomicin was effected against C difficile isolated from these patients after 12-month treatment [&lt;ulink linkID="1274949" linkType="Reference"&gt;1274949&lt;/ulink&gt;], [&lt;ulink linkID="1277578" linkType="Reference"&gt;1277578&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012, data from a post-hoc subgroup analysis  that assessed outcomes in cancer patients from the two phase III studies &lt;ulink linkID="61635" linkType="Protocol"&gt;NCT00314951&lt;/ulink&gt; and &lt;ulink linkID="9763" linkType="Protocol"&gt;NCT00468728&lt;/ulink&gt; were presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London, UK. Significantly higher clinical cure and sustained clinical cure rates were observed in fidaxomicin-treated patients compared with vancomycin-treated patients. The respective clinical cure and sustained clinical cure rates were 97.3 and 83.6% for the fidaxomicin arm, compared with 87.5 and 61.3% for the vancomycin arm. Significantly lower rates of recurrence were also observed in the fidaxomicin group (14.1%) compared with the vancomycin group (30%) [&lt;ulink linkID="1276619" linkType="Reference"&gt;1276619&lt;/ulink&gt;], [&lt;ulink linkID="1276622" linkType="Reference"&gt;1276622&lt;/ulink&gt;], [&lt;ulink linkID="1291603" linkType="Reference"&gt;1291603&lt;/ulink&gt;]. In May 2012, further data from the retrospective subpopulation analysis of cancer patients with CDAD (n = 183) were reported. Cancer patients with CDAD had a slower time to resolution of diarrhea (100 h) compared with non-cancer patients (55 h). The respective time to resolution of diarrhea was faster in cancer patients treated with fidaxomicin (74 h) compared with those on vancomycin (123 h); the safety profile was comparable between both therapy arms [&lt;ulink linkID="1291603" linkType="Reference"&gt;1291603&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2010, pooled data from the two phase III studies (NCT00314951 and NCT00468728), which included 1164 patients were presented at the 50th Annual ICAAC meeting in Boston, MA. The results demonstrated that fidaxomicin was superior to vancomycin in the treatment of CDI recurrence and reduction of relapse. Data from a subanalysis of patients that had experienced a prior CDI episode (n = 178) and recurred within 3 months of entering the study (n = 128) showed that post-treatment, 35.5% of the vancomycin patients (n = 22/62) experienced another recurrence compared to 19.7% in patients (n = 13/66) treated with fidaxomicin; this equated to a 45% reduction in repeat CDI recurrence [&lt;ulink linkID="1130782" linkType="Reference"&gt;1130782&lt;/ulink&gt;]. In further data reported at the meeting, time-to-recurrence was demonstrated to be significantly different between the fidaxomicin and vancomycin arms with recurrence within 2 weeks in 8% of fidaxomicin patients and 27% of vancomycin patients. The 4-week recurrence figures were 20 and 36%, respectively. The risk of recurrence was found to be 2.7-fold greater in patients &amp;gt;/= 75 years of age compared with those &amp;lt; 55 [&lt;ulink linkID="1126259" linkType="Reference"&gt;1126259&lt;/ulink&gt;]. Data from stool samples demonstrated a clinical cure rate of 91.9% in fidaxomicin-treated patients compared with 90.2% in the vancomycin arm. The rate of recurrence was 13% in the fidaxomicin cohort and 24.6% in the vancomycin group with a global cure rate of 78.6% in the fidaxomicin group and 66.4% in the vancomycin arm [&lt;ulink linkID="1126255" linkType="Reference"&gt;1126255&lt;/ulink&gt;]. In October 2010, similar combined data were reported at the 48th Annual Meeting of the Infectious Disease Society of America in Vancouver, Canada [&lt;ulink linkID="1141484" linkType="Reference"&gt;1141484&lt;/ulink&gt;]. In May 2011, additional analysis of data from the two trials was presented at the American Geriatric Society (AGS) annual meeting in National Harbor, MD. Advancing age was associated with the reduction in sustained cure, prolonged time to resolution of diarrhea and increased risk of disease recurrence, independent of fidaxomicin or vancomycin treatment. Fidaxomicin treatment also demonstrated a 54% lower risk of recurrence and increased probability of cure without recurrence compared to vancomycin. In addition, regression analysis showed that advancing age above the age of 40 for each decade, was associated with a 17% reduction in CDI cure probability, a 17% increase in recurrence within 30 days from the end of treatment and a 13% reduction in the probability of a 30-day cure without recurrence in the per protocol population of patients (n = 999) treated with fidaxomicin or vancomycin from the two studies [&lt;ulink linkID="1191445" linkType="Reference"&gt;1191445&lt;/ulink&gt;]. Further analysis was presented at the May 2011 Digestive Disease Week conference in Chicago, IL. The first analysis aimed to identify risk factors after end of therapy (EOT) associated with early recurrence (within 2 weeks after EOT) compared with late recurrence (during weeks 3 and 4 after EOT). The data showed that  67.9% of recurrences occurred within 2 weeks of EOT. Treatment with fidaxomicin resulted in a significant reduction of early recurrence compared with vancomycin; however, late recurrence was the same in both treatment arms. Elevated white blood cell counts and low albumin levels at EOT and exposure to concomitant antibiotics during the follow-up period were associated with a higher risk of late recurrence. The second analysis measured the concentration of fidaxomicin and its metabolite OP-1118 in the plasma and feces of fidaxomicin-treated patients. The data showed that fidaxomicin stayed at the site of infection, with fecal concentrations  &amp;gt; 10,000 times higher than plasma concentrations for both fidaxomicin and OP-1118  [&lt;ulink linkID="1190175" linkType="Reference"&gt;1190175&lt;/ulink&gt;]. Later in May 2011, similar data were presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy. Data from a third analysis were also reported demonstrating alcohol abuse to be associated with a higher rate of recurrence. However, compared with vancomycin, fidaxomicin was associated with lower recurrence rates regardless of alcohol consumption [&lt;ulink linkID="1190428" linkType="Reference"&gt;1190428&lt;/ulink&gt;]. In August 2011, pooled data from a subgroup analysis of the two phase III trials evaluating the efficacy of fidaxomicin in comparison to vancomycin for CDAD in adults (n = 999) were published. CDAD patients treated with fidaxomicin while using concomitant antibiotics showed a significantly higher clinical cure rate (90%), compared with the corresponding vancomycin group (79.4%) at the end of treatment. Fidaxomicin was also statistically superior to vancomycin in global cure rate (72.7% compared with 59.4%) at the end of treatment. However, it was observed that the use of concomitant antibiotic therapy with either fidaxomicin or vancomycin compromised CDAD response. Clinical cure rate was 84.4% for the combined fidaxomicin and vancomycin treatment groups, compared with 92.6% for patients who did not receive concomitant antibiotics. Global cure rate was higher in patients that did not receive concomitant antibiotics (74.7%), compared with those that did (65.8%). In addition, concomitant antibiotic use was associated with a higher rate of recurrence [&lt;ulink linkID="1215315" linkType="Reference"&gt;1215315&lt;/ulink&gt;], [&lt;ulink linkID="1215274" linkType="Reference"&gt;1215274&lt;/ulink&gt;]. In October 2011, a retrospective analysis of data from two randomized, double-blind, non-inferiority, phase III studies comparing the efficacy of fidaxomicin with vancomycin in CDAD patients (n = 1164) were presented at the 49th Annual IDSA Meeting in Boston, MA. In the intent-to-treat (ITT) population, clinical cure rates for fidaxomicin were non-inferior to vancomycin: fidaxomicin achieved a 37% reduction in persistent diarrhea or death compared with vancomycin during the first 12 days.  In the overall analysis, fidaxomicin achieved a 40% reduction in persistent diarrhea, disease recurrence or death  compared with vancomycin over  40 days [&lt;ulink linkID="1232023" linkType="Reference"&gt;1232023&lt;/ulink&gt;], [&lt;ulink linkID="1232837" linkType="Reference"&gt;1232837&lt;/ulink&gt;], [&lt;ulink linkID="1232975" linkType="Reference"&gt;1232975&lt;/ulink&gt;].   In April 2012, similar data were presented at the 22nd ECCMID in London, UK. Data showed risk of failure for the treatment to be increased with shorter duration of administration (&amp;lt;9 days), lower serum albumin, and  the presence of cancer, leukocytosis or renal failure [&lt;ulink linkID="1277620" linkType="Reference"&gt;1277620&lt;/ulink&gt;], [&lt;ulink linkID="1277578" linkType="Reference"&gt;1277578&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2007, a randomized, double-blind phase III trial (&lt;ulink linkID="9763" linkType="Protocol"&gt;NCT00468728&lt;/ulink&gt;; 101.1.C.004; 101.1.C.004; OPT-80-004) was initiated to evaluate the safety and efficacy of fidaxomicin versus vancomycin in patients with CDAD. Patients (expected n = 535) were to receive fidaxomicin or vancomycin  and the primary endpoint was the cure rate [&lt;ulink linkID="1073393" linkType="Reference"&gt;1073393&lt;/ulink&gt;]. Enrollment was completed in November 2009 [&lt;ulink linkID="1056481" linkType="Reference"&gt;1056481&lt;/ulink&gt;]. In February 2010, top-line results were reported; fidaxomicin had a cure rate of 91.7% compared to 90.6% for vancomycin, and was not inferior. Fidaxomicin had significantly lower recurrence rates, with 12.8% of treated patients suffering a recurrence compared to 25.3% for vancomycin. In addition 79.6% of patients treated with fidaxomicin achieved a global cure compared to 65.5% in vancomycin-treated patients [&lt;ulink linkID="1073269" linkType="Reference"&gt;1073269&lt;/ulink&gt;]. In April 2010, similar data were presented at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria [&lt;ulink linkID="1089092" linkType="Reference"&gt;1089092&lt;/ulink&gt;]. Further data were presented in May 2010 at the DDW meeting in New Orleans, LA. Patients who received concomitant antibiotics during the trial had a lower cure rate than patients who did not receive concomitant antibiotic treatment (86.1% vs 98.4%, respectively); however, patients treated with fidaxomicin and concomitant antibiotics demonstrated  lower recurrences of infection compared to those treated with vancomycin (17.6% and  29.5%, respectively) [&lt;ulink linkID="1099826" linkType="Reference"&gt;1099826&lt;/ulink&gt;]. In September 2010, further data were presented at the 50th ICAAC meeting in Boston, MA. There was no correlation between the baseline MIC and clinical success/failure for either fidaxomicin or vancomycin. No resistance to fidaxomicin developed during the trial, and no geographical differences in susceptibility were noted [&lt;ulink linkID="1127315" linkType="Reference"&gt;1127315&lt;/ulink&gt;]. In February 2012, further data were published. In the trial, 87.7% of fidaxomicin-treated patients  achieved resolution of diarrhea and no further need for treatment compared with 86.8% of vancomycin-treated patients. Fidaxomicin produced significantly superior rates of sustained clinical response through 25 days after the end of treatment  and significantly lower recurrence rates within 4 weeks of treatment. In patients who achieved clinical cure with vancomycin, 26.9% had a recurrence of disease, compared with  only 12.7%  of patients who achieved a clinical cure with fidaxomicin.  Treatment-related adverse events were not significantly different between groups [&lt;ulink linkID="1274427" linkType="Reference"&gt;1274427&lt;/ulink&gt;], [&lt;ulink linkID="1274691" linkType="Reference"&gt;1274691&lt;/ulink&gt;]. In March 2012, similar data were presented at the 22nd ECCMID in London, UK [&lt;ulink linkID="1276619" linkType="Reference"&gt;1276619&lt;/ulink&gt;], [&lt;ulink linkID="1277615" linkType="Reference"&gt;1277615&lt;/ulink&gt;], [&lt;ulink linkID="1277578" linkType="Reference"&gt;1277578&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2006, the FDA had approved Optimer's phase IIb/III  trial protocols [&lt;ulink linkID="648913" linkType="Reference"&gt;648913&lt;/ulink&gt;]. In April 2006, the first trial was initiated in the US. The randomized, double-blind, active control, parallel-group study would compare the safety and efficacy of fidaxomicin with vancomycin in patients with CDAD [&lt;ulink linkID="741137" linkType="Reference"&gt;741137&lt;/ulink&gt;], [&lt;ulink linkID="741063" linkType="Reference"&gt;741063&lt;/ulink&gt;]. In March 2007, the FDA and DSMB approved the advance of the comparative trial (PAR101.C.003) into phase III, following their analysis of phase IIb  data,  which raised no safety issues  [&lt;ulink linkID="774405" linkType="Reference"&gt;774405&lt;/ulink&gt;]. In May 2007, the  European and North American phase III trial (&lt;ulink linkID="61635" linkType="Protocol"&gt;NCT00314951&lt;/ulink&gt;; PAR-101/OPT-80 2B/3; 101.1.C.003) began. The double-blind, randomized, parallel group study was to determine the safety and efficacy of fidaxomicin (200 mg  bid) versus vancomycin (125 mg four times daily) in 664 patients. The primary endpoint was cure rate and the secondary endpoint was recurrence within 4 weeks [&lt;ulink linkID="789247" linkType="Reference"&gt;789247&lt;/ulink&gt;]. In July 2008, enrollment was completed  [&lt;ulink linkID="927371" linkType="Reference"&gt;927371&lt;/ulink&gt;]. In November 2008, topline data from the trial were reported. In the multicenter trial, 629 patients received 200 mg of fidaxomicin bid or 125 mg vancomycin four times daily. A total of 92.1% of patients receiving fidaxomicin achieved clinical cure, compared with 89.8% in the vancomycin group. Patients in the fidaxomicin arm had a global cure of 77.7%, compared with vancomycin at 67.1%. Furthermore, 13.3% of patients treated with fidaxomicin experienced a recurrence, compared with 24.0% of patients receiving vancomycin. Fidaxomicin was well tolerated [&lt;ulink linkID="961734" linkType="Reference"&gt;961734&lt;/ulink&gt;]. A subgroup analysis from the trial was reported in May 2009 at the  European Congress of Clinical Microbiology and Infectious Diseases in Helsinki, Finland. The efficacy of the two drugs was similar in subgroups of patient status (in or outpatient), age, and strain type. Fidaxomicin reduced recurrence rates in all patient status and age groups, and a similar recurrence rate was seen in the strain subgroup analysis [&lt;ulink linkID="1010373" linkType="Reference"&gt;1010373&lt;/ulink&gt;]. When taking into account albumin levels, white blood cell count, temperature and strain types of CDI, fidaxomicin still showed a lower recurrence rate relative to vancomycin treatment. This was also true for patients with non-BI (NAP1/027) strains [&lt;ulink linkID="1031319" linkType="Reference"&gt;1031319&lt;/ulink&gt;]. In September 2009, data were presented at the 49th ICAAC meeting in San Francisco, CA, from an analysis of recurrence rates after treatment. Of the 432 patients in the per protocol analysis who were cured, 13.3% on fidaxomicin and 24% on vancomycin experienced recurrence. Recurrence was also seen to a greater extent in  those who had received any CDI-active antibiotics prior to treatment, indicating that fidaxomicin could have greater potential as a first-line therapy  [&lt;ulink linkID="1036924" linkType="Reference"&gt;1036924&lt;/ulink&gt;], [&lt;ulink linkID="1041919" linkType="Reference"&gt;1041919&lt;/ulink&gt;]. Safety data were also presented, showing that the two drugs had similar safety profiles, with drug-related adverse event rates of 9.7% and 9.0% for fidaxomicin and vancomycin, respectively [&lt;ulink linkID="1036925" linkType="Reference"&gt;1036925&lt;/ulink&gt;], [&lt;ulink linkID="1036371" linkType="Reference"&gt;1036371&lt;/ulink&gt;]. Further data showed fidaxomicin was less likely to encourage VRE colonization in patients with CDI than vancomycin [&lt;ulink linkID="1036446" linkType="Reference"&gt;1036446&lt;/ulink&gt;]. In October 2009, data were presented at the 47th Annual Meeting of the Infectious Diseases Society of America in Philadelphia, PA. Diarrhea took 79 h to resolve with fidaxomicin and 105 h to resolve with vancomycin in patients with more pronounced diarrhea. In patients  also receiving antibiotics, global cure rate was 72 and 50% in the fidaxomicin and vancomycin groups, respectively; CDI recurrence rate was 40 and 23%, respectively; and clinical cure rate was 87 and 77% respectively [&lt;ulink linkID="1053357" linkType="Reference"&gt;1053357&lt;/ulink&gt;]. In November 2009, the protocol was amended to make 'global cure'  a secondary endpoint [&lt;ulink linkID="1054363" linkType="Reference"&gt;1054363&lt;/ulink&gt;]. In April 2010, similar data were presented at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria [&lt;ulink linkID="1089092" linkType="Reference"&gt;1089092&lt;/ulink&gt;].   In September 2010, similar data were presented at the 50th Annual ICAAC meeting in Boston, MA [&lt;ulink linkID="1130782" linkType="Reference"&gt;1130782&lt;/ulink&gt;]. Full data were published in February 2011 [&lt;ulink linkID="1165546" linkType="Reference"&gt;1165546&lt;/ulink&gt;], [&lt;ulink linkID="1165394" linkType="Reference"&gt;1165394&lt;/ulink&gt;], [&lt;ulink linkID="1166398" linkType="Reference"&gt;1166398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2005, data  were presented at the 45th ICAAC meeting in Washington DC. In an open-label, phase IIa study of 45 patients with mild-to-moderate CDAD, patients who received twice-daily doses of 50, 100 and 200 mg for 10 days showed clinical response rates of 86, 87 and 100%, respectively [&lt;ulink linkID="641458" linkType="Reference"&gt;641458&lt;/ulink&gt;], [&lt;ulink linkID="643261" linkType="Reference"&gt;643261&lt;/ulink&gt;], [&lt;ulink linkID="641815" linkType="Reference"&gt;641815&lt;/ulink&gt;].   Further data were reported in February 2006. The dose-ranging study evaluated cure rates, relief of symptoms of CDAD, time to resolution of diarrhea, and clinical recurrence. The drug was well tolerated by all subjects, with an overall cure rate of over 91% and a 5% recurrence rate of symptoms [&lt;ulink linkID="648913" linkType="Reference"&gt;648913&lt;/ulink&gt;]. In June 2008, data from the trial were presented at the ninth Biennial Congress of the Anaerobe Society of the Americas in Long Beach, CA, showing no difference in cure rate between patients with and without infection with the BI/NAP1/027 strain of C difficile [&lt;ulink linkID="920767" linkType="Reference"&gt;920767&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In February 2013, phase I trials were underway in Japan for CDAD [&lt;ulink linkID="1365353" linkType="Reference"&gt;1365353&lt;/ulink&gt;]. In September 2014, clinical data were presented at the 54th ICAAC Meeting in Washington, DC. After multiple doses of 200 mg, mean fidaxomicin and OP-1118 fecal concentration was to be 2669.2 and 960.9 microg/g in the Japanese group and 2180.9 and 1163.3 microg/g in the Caucasian group, respectively. Cmaz values were 9, 9, 9, 9, 8 and 9 microg/ml; AUC values were 5, 7, 8, 9, 8 and 9 ng.h/ml; half-life values were 6, 7, 8, 9, 6 and 7 h; Tmax values were 9, 9, 8, 9, 8 and 9 h in the 100 mg, single dose Japanese, 200 mg, single dose Japanese, 200 mg single dose (Caucasian), 100 mg multiple dose (Japanese, 200 mg multiple dose Japanese and 200 mg multiple dose Caucasia groups, respectively. Treatment related adverse events (AEs) were reported in three subjects each in the single and multiple dose groups [&lt;ulink linkID="1589974" linkType="Reference"&gt;1589974&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, data from phase I, open-label, two-period, randomized, crossover study that evaluated the effect of single cyclosporine dose on the single dose pharmacokinetics of &lt;ulink linkID="42147" linkType="Drug"&gt;fidaxomicin&lt;/ulink&gt; in healthy male subjects (n = 14) were presented at the 51st ICAAC meeting in Chicago, IL. The mean Cmax values of fidaxomicin was 4.15-fold higher and that of OP-1118 (metabolite) was 9.51-fold higher following the combination treatment than that seen following the administration of fidaxomicin alone. Similarly, the respective mean AUC 0 to infinity and 0 to t values were up to 1.92 and 2.5-fold higher  for fidaxomicin and up to 4.1 and 4.2-fold higher for OP-1118 following the combination treatment than following fidaxomicin alone [&lt;ulink linkID="1219512" linkType="Reference"&gt;1219512&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, data from an open-label, monosequence, crossover study assessing the effect of fidaxomicin on the pharmacokinetics of &lt;ulink linkID="51644" linkType="Drug"&gt;digoxin&lt;/ulink&gt; in healthy subjects (n = 14) were presented at the 51st ICAAC meeting in Chicago, IL. The Cmax, Tmax, AUC (0 to 24) and half life values were 1.52 ng/ml, 1 h, 11.7 ng/ml/h and 38.8 h, respectively for digoxin alone compared with 1.79 ng/ml, 1 h, 12.9 ng/ml/h and 41.6 h when administered in combination with fidaxomicin [&lt;ulink linkID="1219361" linkType="Reference"&gt;1219361&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, data from a randomized, two-period, two-way, crossover, phase I study assessing the pharmacokinetics of fidaxomicin in patients with C difficile-associated diarrhea were presented at the 51st ICAAC meeting in Chicago, IL. Patients received fidaxomicin 200 or 400 mg, po under fasted or fed conditions, in a crossover sequence. Tmax and mean half-life values for fidaxomicin and its major metabolite OP-1118 were in the range of 1 to 2 h, and 8.36 to 10.1 h, respectively. Fidaxomicin or OP-1118 Cmax and AUC (0 to t) values were not increased dose-proportionally when fidaxomicin dosing was amplified from 200 to 400 mg under fasted state. The Cmax values for fidaxomicin and OP-1118 were reduced by 21.5 and 33.4%, respectively in the fed state compared with the fasted state; Tmax was increased by 1 h. Fed state AUC (0 to t) for fidaxomicin and OP-1118 was equivalent to the fasted state, but Cmax was not [&lt;ulink linkID="1219359" linkType="Reference"&gt;1219359&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2005, clinical data  were presented at the 45th ICAAC meeting in Washington DC.  In a phase Ib study, fidaxomicin (150, 300 and 450 mg/day for 10 days) was well tolerated in 24 healthy subjects [&lt;ulink linkID="641458" linkType="Reference"&gt;641458&lt;/ulink&gt;], [&lt;ulink linkID="643261" linkType="Reference"&gt;643261&lt;/ulink&gt;], [&lt;ulink linkID="641815" linkType="Reference"&gt;641815&lt;/ulink&gt;].   Similar data from the phase Ib trial were published in April 2008 [&lt;ulink linkID="892343" linkType="Reference"&gt;892343&lt;/ulink&gt;], [&lt;ulink linkID="892705" linkType="Reference"&gt;892705&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2002,  Optimer was planning to initiate clinical studies for CDAD in mid-2003 [&lt;ulink linkID="467209" linkType="reference"&gt;467209&lt;/ulink&gt;]. The phase I trials were underway by 2004 [&lt;ulink linkID="546733" linkType="reference"&gt;546733&lt;/ulink&gt;], [&lt;ulink linkID="546830" linkType="reference"&gt;546830&lt;/ulink&gt;] and had been completed by October 2004 [&lt;ulink linkID="568699" linkType="Reference"&gt;568699&lt;/ulink&gt;], [&lt;ulink linkID="567818" linkType="Reference"&gt;567818&lt;/ulink&gt;]. At that time, clinical data on fidaxomicin were presented at the 44th ICAAC meeting in Washington, DC. A total of 16 healthy volunteers were administered placebo or single oral doses of fidaxomicin at 100, 200, 300 or 450 mg. Five adverse events were reported (none were found to be drug related) and one major metabolite, OP-1118, was detected  [&lt;ulink linkID="567818" linkType="Reference"&gt;567818&lt;/ulink&gt;], [&lt;ulink linkID="567939" linkType="Reference"&gt;567939&lt;/ulink&gt;].   Similar data were published in April 2008 [&lt;ulink linkID="892343" linkType="Reference"&gt;892343&lt;/ulink&gt;], [&lt;ulink linkID="892705" linkType="Reference"&gt;892705&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In October 2018, clinical data from an open-label study which evaluated the efficacy of a 30-day treatment of fidaxomicin in adult patients with multiple recurrent CDI were presented at the 2018 IDWeek in San Francisco, CA. Patients with at least two episodes of recurrent CDI (n = 29) initiated fidaxomicin 200 mg for 30 days when a new episode of CDI was experienced. Clinical resolution of CDI-related symptoms at the completion of 30-day course of fidaxomicin was observed in 24 patients. A total of 22 patients had a sustained clinical response with the overall cure rate of 76%. There were statistically significant improvements (p &amp;lt; 0.05) in multiple domains of quality of life as assesses by RAND-36 Item Health Survey  [&lt;ulink linkID="2078103" linkType="Reference"&gt;2078103&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2018, data from a national retrospective study which evaluated the use of concomitant non- CDI antibiotic and death among a national cohort of veterans with CDI treated with metronidazole, vancomycin or fidaxomicin, were presented at the 2018 IDWeek in San Francisco, CA. Patients received po or iv metronidazole, po or per rectum vancomycin or fidaxomicin. A total of 4925 patients received concomitant non-CDI antibiotics and 4592 patients received no concomitant non-CDI antibiotics. The unadjusted and adjusted hazard ratio of the risk of all-cause mortality among patients who received any concomitant non-CDI antibiotic was 5.74 and 2.39, respectively. These results indicated that any concomitant antibiotic use increased the risk of death [&lt;ulink linkID="2078229" linkType="Reference"&gt;2078229&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2017, clinical data from a real-world, non-interventional, multicenter, prospective real world observational study (DISCOVER Registry), which evaluated the efficacy of fidaxomicin, a macrocyclic agent, in patients with Clostridium difficile infection (CDI) from 15 US centers were presented at the 2017 ASM Microbe Conference in New Orleans, LA. Patients (n = 59) received fidaxomicin. In an assessment at day 14, 17 patients were hospitalized, 40 patients were discharged, death occurred in 1 patient and the response was unknown in 1 patient. At day 14, of 56 patients, clinical cure was achieved by 46 patients, treatment was continued in 6 patients, and treatment failure was observed in 4 patients. On admission or &amp;lt;/= 24 h, CDI was observed in 15 patients, 22 patients had prior history of CDI with mean number of 2.73 CDI episodes; and mean days of fidaxomicin treatment was 8.4 days. a majority of fidaxomicin treated patients achieved clinical cure; and within 90 days of follow-up, the recurrence rate was 10% [&lt;ulink linkID="1934230" linkType="Reference"&gt;1934230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, clinical data from a retrospective, observational study, which evaluated the efficacy of fidaxomicin for the potential treatment of Clostridium difficile infection (CDI) in hospitalized patients at high risk of recurrence were presented at the 2017 ASM Microbe Conference in New Orleans, LA. Patients received fidaxomicin treatment. Of 120 patients who received treatment, a total of 36 patients met the algorithm criteria, while 84 patients were excluded. According to the algorithm, high risk CDI patients achieved a high success rate which was similar to clinical studies; and recurrence or readmission related to CDI was not reported [&lt;ulink linkID="1934231" linkType="Reference"&gt;1934231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015,  resulyts from a randomized study performed to evaluate the efficacy of fidaxomicin, in patients (n = 34) with Clostridium difficile infection were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. Significant overall reduction of toxin A concentration (p = 0.003), particularly at follow-up (p = 0.02) was observed with fidaxomicin; similar reduction was observed with toxin B (p = 0,07) but the result was not significant [&lt;ulink linkID="1692762" linkType="Reference"&gt;1692762&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, results from an open-label, single arm study in children aged from 6 months to &amp;lt; 18 years (n = 38) were presented at the 25th ECCMID in Copenhagen, Denmark. Plasma fidaxomicin levels were low in children and were comparable to those observed in adults. During the study period, nine adverse events were observed and none of them were regarded to be associated with fidaxomicin. Overall, 92.1% of patients had positive clinical response, of which 28.6% had recurrence. Sustained clinical response was reported by 65.8% of patients [&lt;ulink linkID="1654657" linkType="Reference"&gt;1654657&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, clinical data were presented at the 52nd ICAAC Meeting in San Francisco, CA.  Transplant recipients with CDAD received fidaxomicin (n = 8) and oral vancomycin and/or metronidazole (control group, n = 24). After completion of CDAD therapy, no patients had vancomycin-resistant enterococci colonization in the fidaxomicin group when compared with three patients in the control group. In the fidaxomicin versus control group, the rates of clinical cure were 75 versus 92% and the recurrence rates were 13 versus 8%. In the fidaxomicin group, the mean time to resolution of diarrhea was 11 days compared with 6 days in the control group. After fidaxomicin initiation, the mean time to resolution of diarrhea was 4 days. Fidaxomicin was found to be well tolerated [&lt;ulink linkID="1320893" linkType="Reference"&gt;1320893&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, data from an open-label, monosequence crossover study that evaluated the effect of fidaxomicin on the pharmacokinetics of &lt;ulink linkID="44303" linkType="Drug"&gt;midazolam&lt;/ulink&gt;, &lt;ulink linkID="44305" linkType="Drug"&gt;omeprazole&lt;/ulink&gt; and &lt;ulink linkID="44375" linkType="Drug"&gt;warfarin&lt;/ulink&gt;, in healthy male subjects (n = 24) were presented at the 51st ICAAC meeting in Chicago, IL. Fidaxomicin was not found to alter the capacity of CYP2C9, CYP2C19 and CYP3A4/4 to metabolize S-warfarin, omeprazole or midazolam, respectively. The pharmacokinetics of both enantiomers of warfarin and that of midazolam and 1-hydroxymidazolam were found to be similar following the single oral dose of cocktail (midazolam, omeprazole and warfarin) on day 1 and following single po dose in combination with fidaxomicin on day 21 [&lt;ulink linkID="1219511" linkType="Reference"&gt;1219511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Oral suspension formulation&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In  October 2018, Astellas listed the drug as being in phase III development in Europe for CDI in pediatric patients, presumed to be for the oral suspension formulation [&lt;ulink linkID="2078723" linkType="Reference"&gt;2078723&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January  2015, a multicenter, investigator-blind, randomized, parallel group phase III trial (&lt;ulink linkID="208639" linkType="Protocol"&gt;NCT02218372&lt;/ulink&gt;; 2819-CL-0202, 2013-000508-40; SUNSHINE) was initiated in pediatric subjects with CDAD  (expected n = 144) in the US, Canada, Belgium, France, Germany, Hungary, Italy, Poland, Romania, Slovakia and Spain to evaluate the safety and efficacy of fidaxomicin oral suspension or  fidaxomicin tablets and &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt; oral liquid or  capsules.  In February 2018, the trial was expected to complete in March 2018  [&lt;ulink linkID="1587702" linkType="Reference"&gt;1587702&lt;/ulink&gt;]. In April 2018, the trial was completed [&lt;ulink linkID="1587702" linkType="Reference"&gt;1587702&lt;/ulink&gt;]. In October 2018, clinical data were presented at the 2018 IDWeek in San Francisco, CA. In fidaxomicin and vancomycin groups, confirmed clinical response at day-12 (primary endpoint) was reported in 77.6 and 70.5% of patients, respectively; recurrence of C difficile infection was reported in 11.8 and 29% of patients, respectively; and global cure was reported in 68.4 and 50% of patients, respectively. Overall, &amp;gt;/= 1 treatment emergent adverse events were reported in 73.5 and 75% of patients in fidaxomicin and vancomycin arms, respectively [&lt;ulink linkID="2078091" linkType="Reference"&gt;2078091&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2012, a multicenter, open-label, interventional, uncontrolled, phase IIa  study was initiated in pediatric  patients (n = 32) aged from 6 months to 18 years  with CDAD to assess the safety, tolerability and pharmacokinetics of fidaxomicin oral suspension. At that time, the study was expected to complete in January 2014 [&lt;ulink linkID="1468786" linkType="Reference"&gt;1468786&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2010, an IND was filed [&lt;ulink linkID="1089904" linkType="Reference"&gt;1089904&lt;/ulink&gt;].  In January 2011, the oral suspension formulation was in phase II development [&lt;ulink linkID="1161056" linkType="Reference"&gt;1161056&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2016, preclinical data were presented at the 2016 ASM Microbe Conference in Boston, MA. In all treatment groups of mice, fecal bacterial diversity was similar before antibiotic administration and was decreased significantly 3 days after therapy. Fidaxomicin (30 mg/ml) treatment resulted in reduced loss of bacterial community evenness, evidenced by Shannon diversity index scores. Loss of bacterial community was lower and recovery was faster with fidaxomicin treatment, compared with vancomycin. verall, all fidaxomicin exposed mice (except one) remained resistant to CDI and correlated with reduced disruption and rapid recovery of intestinal microbiome [&lt;ulink linkID="1771533" linkType="Reference"&gt;1771533&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. After 24 and 48 h, fidaxomicin exposed washed spores showed no vegetative cell growth whereas germination and proliferation of vancomycin exposed washed spores behaved similarly as controls [&lt;ulink linkID="1694422" linkType="Reference"&gt;1694422&lt;/ulink&gt;]. Additional data presented at the conference showed fidaxomicin, its active metabolite OP-1118, and surotomycin to have potent in vitro activity against all genotypes of toxin-positive C difficile [&lt;ulink linkID="1693346" linkType="Reference"&gt;1693346&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, preclinical data were presented at the Digestive Disease Week 2015 in Washington DC. Data demonstrated that minimal disruption of the intestinal microbiota was caused and its susceptibility to vancomycin-resistant Enterococci and extended-spectrum beta-lactamase-producing Klebsiella pneumonia colonization was not rendered by fidaxomicin and metronidazole exposure compared with vancomycin [&lt;ulink linkID="1660299" linkType="Reference"&gt;1660299&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2014, preclinical data were presented at the 54th ICAAC Meeting in Washington DC. Against 379 toxin-positive isolates of C difficile, the respective MIC50 values for fidaxomicin, OP-1118, metronidazole, vancomycin, &lt;ulink linkID="52573" linkType="Drug"&gt;amoxicillin-clavulanate&lt;/ulink&gt;, &lt;ulink linkID="44370" linkType="Drug"&gt;clindamycin&lt;/ulink&gt;, &lt;ulink linkID="12978" linkType="Drug"&gt;moxifloxacin&lt;/ulink&gt; and &lt;ulink linkID="44384" linkType="Drug"&gt;ceftriaxone&lt;/ulink&gt; were 0.25, 8, 0.5, 1, 1, 4, 2 and 32 microg/ml  [&lt;ulink linkID="1589220" linkType="Reference"&gt;1589220&lt;/ulink&gt;]. Further data were presented at the same conference.The mean log reduction with fidaxomicin (2.17) was significantly greater when compared with vancomycin (0.66) and metronidazole (0.44) [&lt;ulink linkID="1590794" linkType="Reference"&gt;1590794&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, preclinical data were presented at the 53rd ICAAC Meeting in Denver, CO.  In the 20 days gut model treated with fidaxomicin (200 mg/l bid), the C difficile total viable counts (TVCs) were reduced by day 5 and toxin titres were reduced by day 7 with no recurrence. Reductions in TVCs and spore counts to the limit of detection were observed on the second 5 days fidaxomicin pulse [&lt;ulink linkID="1472319" linkType="Reference"&gt;1472319&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 23rd ECCMID  in Berlin, Germany. Microbial activity against Kocuria rhizophila and staphylococcus aureus  was  retained by spores exposed to 1 and 30 min fidaxomicin after washing. In washed spore samples, the concentration of fidaxomicin was approximately 4 to 8 mg/l.  In A, B and C models of human gut, fidaxomicin persisted at a concentration of 5 to 10 mg/l for 21 days when compared with clindamycin and vancomycin which were washed out within approximately 5 days [&lt;ulink linkID="1405964" linkType="Reference"&gt;1405964&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, preclinical data on spontaneous resistance were presented at the 22nd ECCMID in London, UK. Mutation frequencies to fidaxomicin were low, with a frequency of spontaneous resistance of &amp;lt;1.4X10(-9) to &amp;lt;4.13X10(-9), with no resistance developing at 8-fold MIC and occasional resistance at 4-fold MIC [&lt;ulink linkID="1277622" linkType="Reference"&gt;1277622&lt;/ulink&gt;], [&lt;ulink linkID="1277578" linkType="Reference"&gt;1277578&lt;/ulink&gt;]. In October 2012, similar and further data were presented at IDweek 2012 in San Diego, CA.  Fidaxomicin plus rifamycin or rifaximin showed synergistic activity but fidaxomicin plus vancomycin or OP-1118 did not. gainst C difficile ATCC 700057 (antibiotic sensitive), 700057-8A (rifaximin-elevated MIC) and 700057-6 (fidaxomicin-elevated MIC) strains, fidaxomicin showed MIC values of 0.25, 0.125 and 4 microg/ml, compared with 0.016, 0.5 and 0.016 for rifamycin.  [&lt;ulink linkID="1331582" linkType="Reference"&gt;1331582&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; In September 2007, fidaxomicin data were presented at the 47th ICAAC meeting in Chicago, IL. Fidaxomicin's major metabolite, OP-1118, demonstrated selective antimicrobial activity against C difficile; both fidaxomicin and OP-1118 had limited fecal binding properties [&lt;ulink linkID="830386" linkType="Reference"&gt;830386&lt;/ulink&gt;]. In September 2013, further data were presented at the 53rd ICAAC Meeting in Denver, CO. The MIC50/90 values were 0.25/1 microg/ml for fidaxomicin and 2/8 microg/ml for OP-1118 against 440 toxin-positive C difficile isolates when compared with the other antimicrobials tested [&lt;ulink linkID="1472949" linkType="Reference"&gt;1472949&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2004 and December 2005, preclinical data were presented at the 45th and 44th ICAAC meetings in Washington DC. Fidaxomicin selectively killed gram-positive anerobes, with little activity against other species tested. The anticlostridial activity of fidaxomicin was superior to that of a number of comparator drugs. Fidaxomicin was non-genotoxic and had a long post-antibiotic effect [&lt;ulink linkID="567818" linkType="Reference"&gt;567818&lt;/ulink&gt;], [&lt;ulink linkID="568226" linkType="Reference"&gt;568226&lt;/ulink&gt;],  [&lt;ulink linkID="568227" linkType="Reference"&gt;568227&lt;/ulink&gt;], [&lt;ulink linkID="568660" linkType="Reference"&gt;568660&lt;/ulink&gt;], [&lt;ulink linkID="568661" linkType="Reference"&gt;568661&lt;/ulink&gt;], [&lt;ulink linkID="641984" linkType="Reference"&gt;641984&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Fidaxomicin is a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum  [&lt;ulink linkID="465351" linkType="reference"&gt;465351&lt;/ulink&gt;], [&lt;ulink linkID="467209" linkType="reference"&gt;467209&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, Optimer entered into a manufacturing services agreement with &lt;ulink linkID="30992" linkType="Company"&gt;Patheon&lt;/ulink&gt; in North America, Europe and other countries. Under the terms of the agreement, Patheon would manufacture and supply fidaxomicin to Optimer in these regions; the agreement expires in December 2016 [&lt;ulink linkID="1273395" linkType="Reference"&gt;1273395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, Optimer and &lt;ulink linkID="28769" linkType="Company"&gt;Biocon&lt;/ulink&gt; entered into an agreement for the manufacture and supply of  fidaxomicin in the US and Canada, which expires in November 2018 [&lt;ulink linkID="1102595" linkType="Reference"&gt;1102595&lt;/ulink&gt;], [&lt;ulink linkID="1273395" linkType="Reference"&gt;1273395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, the EMA's PDCO agreed a pediatric investigation plan (PIP) for the drug in the therapeutic area of infectious diseases [&lt;ulink linkID="1093229" linkType="Reference"&gt;1093229&lt;/ulink&gt;]. In February 2014, PDCO adopted a positive opinion on modification to the agreed PIP  for the treatment of enterocolitis caused by Clostridium difficile [&lt;ulink linkID="1528112" linkType="Reference"&gt;1528112&lt;/ulink&gt;]. In September 2014, the PDCO adopted a positive opinion on further modification to the agreed PIP [&lt;ulink linkID="1595843" linkType="Reference"&gt;1595843&lt;/ulink&gt;]. In February 2017, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for the treatment of enterocolitis caused by Clostridium difficile [&lt;ulink linkID="1899207" linkType="Reference"&gt;1899207&lt;/ulink&gt;]. In January 2018, the PDCO adopted a positive opinion on further modifications to a PIP [&lt;ulink linkID="2004201" linkType="Reference"&gt;2004201&lt;/ulink&gt;]. In November 2018, the EMA's Pediatric Committee adopted a positive opinion on compliance check for  the treatment of enterocolitis caused by Clostridium difficile [&lt;ulink linkID="2102162" linkType="Reference"&gt;2102162&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2008, Optimer received a $1 million annual federal grant to develop fidaxomicin for CDAD. The grant would be renewed for 3 years. It would be used to support a supplementary study of gut flora, additional toxicology and microbiological studies, and a surveillance study to compare the activity of fidaxomicin with existing CDAD treatments [&lt;ulink linkID="865539" linkType="Reference"&gt;865539&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2005, Optimer received a 1-year, $0.73 million SBIR Advanced Technology grant from the National Institute of Allergy and Infectious Diseases (NIAID)   for the development of fidaxomicin [&lt;ulink linkID="628875" linkType="Reference"&gt;628875&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Alan P Johnson, &lt;ulink linkType="Company" linkID="1006631"&gt;Health Protection Agency&lt;/ulink&gt; Centre for Infections, 61 Colindale Avenue, London, UK&lt;/para&gt;&lt;para&gt;Submission date: 23 May 2006&lt;br/&gt;Publication date: 22 January 2007&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;&lt;ulink linkType="Company" linkID="29549"&gt;Optimer Pharmaceuticals Inc&lt;/ulink&gt;'s OPT-80 has good bioavailability in the lower intestine and a lack of efficacy against Gram-negative rod bacteria, so leaves gut flora unharmed. OPT-80 had favorable in vitro activity against Clostridium difficile and a low propensity to cause spontaneous resistance in either animals or humans. In a phase II trial of OPT-80 in adults with C difficile-associated diarrhea (CDAD), 91% were cured. Significantly, recurrence of disease within 6 weeks was &amp;lt; 5%, in contrast to recurrence in up to 33% of patients with existing treatments metronidazole or vancomycin. OPT-80 was well tolerated and there were no drug-related adverse advents. An ongoing phase II/III trial in patients with CDAD was expected to conclude in March 2008. Based on the available data, OPT-80 seems a promising potential treatment option for CDAD. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Clostridium difficile, a Gram-positive, anaerobic, spore-forming bacterium, is a leading cause of antibiotic-associated diarrhea. C difficile-associated diarrhea (CDAD) can arise when patients receive antibiotics (particularly those with a broad spectrum of antibacterial activity) that disturb the balance of the normal gut flora, allowing C difficile cells to increase in number and produce the toxins that cause disease [&lt;ulink linkType="Reference" linkID="745662"&gt;745662&lt;/ulink&gt;]. CDAD occurs most commonly in hospitals or nursing homes where large numbers of individuals receive antibiotics, and infection may spread from person to person by dissemination of spores shed in the feces of infected patients. These spores can survive for prolonged periods in the environment, and may be spread from patient to patient on the hands of healthcare workers, who themselves may be transiently colonized following physical contact with infected patients or contaminated environmental surfaces such as toilets or bedpans [&lt;ulink linkType="Reference" linkID="745667"&gt;745667&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;CDAD varies in severity from mild diarrhea to potentially life-threatening pseudomembranous colitis, involving severe inflammation of the bowel and sloughing of the colonic epithelium [&lt;ulink linkType="Reference" linkID="742369"&gt;742369&lt;/ulink&gt;]. Initial management of CDAD involves discontinuation of the antibiotic that has caused changes in the bowel flora. If this fails, treatment with either metronidazole or &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; may be required [&lt;ulink linkType="Reference" linkID="742564"&gt;742564&lt;/ulink&gt;]. However, recurrence of symptoms after treatment with these drugs occurs in up to one third of patients [&lt;ulink linkType="Reference" linkID="742369"&gt;742369&lt;/ulink&gt;]. In addition, the use of metronidazole may be limited by side effects, including nausea, neuropathy, leukopenia and seizures [&lt;ulink linkType="Reference" linkID="745692"&gt;745692&lt;/ulink&gt;], while widespread use of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; is discouraged as part of the strategy to minimize the emergence and spread of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;-resistant enterococci and staphylococci [&lt;ulink linkType="Reference" linkID="742568"&gt;742568&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The high rates of recurrence of CDAD with current treatments have prompted a search for new agents with improved therapeutic activity. One drug currently under phase III evaluation for the treatment of CDAD is &lt;ulink linkType="Company" linkID="29549"&gt;Optimer Pharmaceuticals Inc&lt;/ulink&gt;'s OPT-80, a narrow-spectrum macrocyclic antibiotic with activity against Gram-positive bacteria, including C difficile. The antibiotic was originally discovered in the 1970s by &lt;ulink linkType="Company" linkID="25219"&gt;Hoechst Marion Roussel SpA&lt;/ulink&gt; who designated it lipiarmycin A3 [&lt;ulink linkType="Patent" linkID="IN260077"&gt;US-03978211&lt;/ulink&gt;]. In the late 1980s and early 1990s it was further investigated by &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt; who redesignated it &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="76143"&gt;76143&lt;/ulink&gt;]. No further development was reported until 2004, when preclinical studies sponsored by Optimer were published by three separate research groups [&lt;ulink linkType="Reference" linkID="658531"&gt;658531&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="658532"&gt;658532&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="658533"&gt;658533&lt;/ulink&gt;]. OPT-80 has been described as an isomeric mixture of configurationally distinct stereoisomers of &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt;, composed of 70 to 100% of R-&lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; and small quantities of related compounds. Optimer entered into a collaboration with &lt;ulink linkType="Company" linkID="28968"&gt;Par Pharmaceutical Companies Inc&lt;/ulink&gt; in 2005 to develop OPT-80. As part of the agreement, the research code name PAR-101 was to be used for future regulatory filings in the US [&lt;ulink linkType="Reference" linkID="598998"&gt;598998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;OPT-80 comprises an unsaturated 18-membered macrocyclic core, with a 7-carbon sugar at C(11) and a 6-deoxy sugar at C(20) [&lt;ulink linkType="Reference" linkID="658532"&gt;658532&lt;/ulink&gt;]. OPT-80 is a member of the tiacumicin family, which are complexes of 18-membered macrocyclic antibiotics naturally produced by a strain of Dactylosporangium aurantiacum isolated from a soil sample collected in Connecticut, USA [&lt;ulink linkType="Reference" linkID="76143"&gt;76143&lt;/ulink&gt;]. The major component of the tiacumicin complex is &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="76143"&gt;76143&lt;/ulink&gt;]. There is some overlap between the tiacumicins and the closely related lipiarmycin family, the structure of &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; being identical to that of lipiarmycin A3 [&lt;ulink linkType="Reference" linkID="76144"&gt;76144&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="PA2888739"&gt;WO-2004014295&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Optically pure R-&lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; is the most active component of OPT-80. The chiral center at C(19) of &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; affects biological activity, and R-&lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; has an R-hydroxyl group attached at this position. The isomer displayed significantly higher activity than other &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt;-related compounds and longer post-antibiotic activity. According to Optimer's patent literature, OPT-80 is an isomeric mixture of the configurationally distinct stereoisomers of &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt;, composed of 70 to 100% of R-&lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; and small quantities of related compounds, such as S-&lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; and lipiarmycin A4 [&lt;ulink linkType="Patent" linkID="PA3223602"&gt;WO-2006085838&lt;/ulink&gt;]. No further details and no analysis of the clinical formulation have apparently been published.&lt;/para&gt;&lt;para&gt;OPT-80 was produced by fermentation of the D aurantiacum subspecies hamdenensis (strain 718C-41) in liquid media containing readily assimilated sources of carbon, nitrogen and inorganic salts. Growth under submerged aerobic conditions at 25 to 35degC and pH 6 to 9 led to the accumulation of OPT-80 after 3 to 15 days of culture. OPT-80 was adsorbed by a resin (such as XAD16) in the culture medium. After 7 or 8 days of fermentation, the resin was separated from the broth by sieving and the tiacumicins eluted using an organic solvent. Several alternative methods for purification were disclosed, including trituration using low-polarity solvents, partitioning between two-phase solvent systems or Sephadex LH-20 column chromatography. Antibiotic components were subsequently separated by silica gel, coil centrifuge chromatography or by both methods. The yields of tiacumicin ranged from 50 to 500 mg/l in the crude extract and &amp;gt; 50 mg/l following HPLC purification. The purity of tiacumicin was &amp;gt; 95% after silica gel and HPLC purification, and 92% after two-phase solvent separation and medium pressure reverse phase liquid chromatography [&lt;ulink linkType="Patent" linkID="PA2888739"&gt;WO-2004014295&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;The idea that OPT-80 might be of particular value in the treatment of CDAD was first proposed in 1991 when researchers from Abbott published data focusing specifically on the activity of OPT-80 against C difficile, both in vitro and in a hamster model of antibiotic-associated colitis [&lt;ulink linkType="Reference" linkID="249148"&gt;249148&lt;/ulink&gt;]. When tested against 15 strains of C difficile in vitro, the MIC50 and MIC90 values were both 0.25 microg/ml. Attempts to detect spontaneous mutants resistant to OPT-80 were unsuccessful, with the frequency of resistance development reported as &amp;lt; 2.8 x 10(-8). In a hamster model of antibiotic-associated colitis produced by oral introduction of a C difficile strain into hamsters pretreated with &lt;ulink linkType="Drug" linkID="44370"&gt;clindamycin&lt;/ulink&gt;, oral administration of OPT-80 (0.2, 1.0 or 5.0 mg/kg) gave 100% protection. In a group of animals treated with comparator drugs, oral treatment with identical doses of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; resulted in prolonged dose-dependent protection; however, mortality was nonetheless observed even in some animals receiving the highest dose of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;. When the experiment was repeated with a different strain of C difficile, both OPT-80 and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; were protective at 5 mg/kg, but not at lower doses [&lt;ulink linkType="Reference" linkID="249148"&gt;249148&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;No further studies were published during the 1990s; however, in 2004, three peer-reviewed papers on the in vitro activity of OPT-80 against C difficile and other anaerobic and intestinal bacteria were published by separate academic research groups, all sponsored by Optimer [&lt;ulink linkType="Reference" linkID="658531"&gt;658531&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="658532"&gt;658532&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="658533"&gt;658533&lt;/ulink&gt;]. In all three studies OPT-80 was active against C difficile. In an in vitro study of OPT-80 against 23 isolates of C difficile, the MIC90 value was 0.25 microg/ml (compared with 2 microg/ml for &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; and 0.5 microg/ml for metronidazole). OPT-80 varied in activity against other clostridial species [&lt;ulink linkType="Reference" linkID="658531"&gt;658531&lt;/ulink&gt;]. In a study of 21 isolates, the MIC90 value for OPT-80 was 0.125 microg/ml (compared with 2 microg/ml for &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; and 0.5 microg/ml for metronidazole). OPT-80 was generally active against Gram-positive anaerobes but lacked activity against Gram-negative anaerobes [&lt;ulink linkType="Reference" linkID="658532"&gt;658532&lt;/ulink&gt;]. In a larger study of activity against 207 isolates of C difficile, OPT-80 had a MIC90 value of 0.0078 microg/ml (compared with 0.25 to 0.5 microg/ml for &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; and 0.0625 to 0.125 microg/ml for metronidazole), although the researchers noted that the MIC values varied depending on which solvents were used to dissolve and dilute OPT-80 [&lt;ulink linkType="Reference" linkID="658533"&gt;658533&lt;/ulink&gt;]. The variation in activity in the different studies was thought to reflect a difference in the strains tested and/or differences in the methods used for susceptibility testing. The researchers from one of these studies suggested that the poor activity of OPT-80 against Gram-negative anaerobic rods may help to maintain colonization resistance, the phenomenon in which the normal bowel microflora protects the gut mucosa against colonization with enteric pathogens, including C difficile [&lt;ulink linkType="Reference" linkID="658531"&gt;658531&lt;/ulink&gt;]. The underlying basis for the selective activity of OPT-80 against particular genera of bacteria is unclear, as the mechanism of action of the drug has not been reported to date.&lt;/para&gt;&lt;para&gt;Further studies by Optimer confirmed the in vitro activity of OPT-80 against C difficile with MIC values of 0.03 to 0.5 mg/ml. OPT-80 had bactericidal activity, causing a 3-log10 decrease in viable count in one strain (9689) over 24 h. A prolonged post-antibiotic effect was also reported, lasting over 24 h after the antibiotic was removed (compared with &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; that had a post-antibiotic effect of &amp;lt; 1 h), indicating a high degree of antibacterial activity. The researchers noted that OPT-80 demonstrated better in vitro activity than &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, killing C difficile significantly more rapidly [&lt;ulink linkType="Reference" linkID="568661"&gt;568661&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Against C difficile, OPT-80 (plated on agar at 4- to 8-fold the MIC value) had no cross-resistance with the licensed antibiotics &lt;ulink linkType="Drug" linkID="2587"&gt;azithromycin&lt;/ulink&gt;, ampicillin, &lt;ulink linkType="Drug" linkID="13757"&gt;telithromycin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt;, metronidazole, &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, labrasol and rifampin. Only the RNA polymerase inhibitor rifampin proved synergistic with OPT-80. OPT-80 had a low propensity to select for resistant mutants (calculated frequency of mutation &amp;lt; 3 x 10(-8)), comparable to that of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; and metronidazole. Resistance of &amp;gt; 2-fold required 13 serial passages (escalating from a concentration half the initial MIC); MIC values of resistant bacteria reached a plateau at the relatively low value of 2 microg/ml [&lt;ulink linkType="Reference" linkID="568660"&gt;568660&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Susceptibility of C difficile to OPT-80 was unaffected by the size of the inoculum (10(5) to 10(8) CFU/ml), concentrations of cations (calcium ions 2.1 to 5.7 mg/dl and magnesium ions 3.3 to 7.5 mg/dl) or variations in commercial media used. Increasing the pH from 6 to 8 increased MIC values with both OPT-80 and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;. MIC values with OPT-80 increased 8-fold when pH was increased from 7.2 to 7.9. It was speculated that this finding may be the result of deprotonated forms of the hydroxyl groups forming charged species with pKa values above that of OPT-80 (pKa = 7.22) that are less permeable to bacterial cells [&lt;ulink linkType="Reference" linkID="641984"&gt;641984&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Animal studies to date have found no significant evidence of toxicity for OPT-80. In mice treated intraperitoneally with OPT-80, the LD50 value was &amp;gt; 500 mg/kg [&lt;ulink linkType="Reference" linkID="249148"&gt;249148&lt;/ulink&gt;], while in rats administered the drug intravenously the LD50 value was approximately 200 mg/kg [&lt;ulink linkType="Reference" linkID="568227"&gt;568227&lt;/ulink&gt;]. There were no side effects in rats receiving up to 1000 mg/kg OPT-80 orally, or in rats or cynomolgus monkeys administered repeated oral doses of OPT-80 at concentrations up to 90 mg/kg for 28 consecutive days [&lt;ulink linkType="Reference" linkID="568227"&gt;568227&lt;/ulink&gt;]. In addition, 10 and 80% of animals in the intermediate- and high-dose groups, respectively, exhibited mild to severe lesions in their tails, the injection site of the poorly soluble compound. OPT-80 was negative at all concentrations in genotoxicity assays, including the in vivo mammalian erythrocyte micronucleus test, although there were mild chromosomal aberrations in a short-term, non-activated chromosomal assay [&lt;ulink linkType="Reference" linkID="568227"&gt;568227&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;Initial pharmacokinetic studies of OPT-80 were conducted by &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt; in male Golden Syrian hamsters receiving a single, oral dose of 25 mg/kg. The drug was not detected in blood samples taken over a 24-h period. In contrast, OPT-80 was present in fecal samples collected at 1, 2, 3, 6, 8 and 24 h after administration, at concentrations of 137, 188, 139, 248, 98 and 58 microg/g, respectively. This result indicated that OPT-80 is able to remain at high concentrations at the site of C difficile infection  the gut [&lt;ulink linkType="Reference" linkID="249148"&gt;249148&lt;/ulink&gt;]. Optimer conducted subsequent studies in Sprague-Dawley rats and cynomolgus monkeys. After administration of repeated oral doses of OPT-80 (&amp;lt;/= 90 mg/kg) to rats for 28 consecutive days, the plasma levels were &amp;lt; 0.5 microg/ml, while after intravenous administration of 20 mg/kg, OPT-80 was cleared from plasma within 10 min, the Cmax value being 2 to 7 microg/ml. The Cmax value of OPT-80 in the plasma of monkeys receiving the drug orally at doses of 30 and 90 mg/kg were 50 to 85 ng/ml and 120 to 420 ng/ml, respectively [&lt;ulink linkType="Reference" linkID="568227"&gt;568227&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a double-blind, placebo-controlled study, individuals (n = 16) received different escalating oral doses of OPT-80 (100 then 300 mg, or 200 then 450 mg; both n = 6) or placebo. Each individual received two escalating doses of OPT-80, with a 1- to 2-week interval between the different doses. Plasma concentrations were generally below the limits of quantification, although they appeared to increase with dose. In the group receiving the highest dose, the mean Tmax, Cmax and AUC values were 1.4 h, 26.5 ng/ml and 76.2 ng.h/ml, respectively. The plasma half-life was approximately 1 to 3 h. Following 200- or 300-mg/kg doses, high fecal concentrations of OPT-80 and a metabolite termed M1 (OP-1118) were observed (26 and 66% of total dose, respectively). Normalized peak fecal concentrations were 52.8 to 160.2 microg/g, consistent with bactericidal effects in the gastrointestinal (GI) tract [&lt;ulink linkType="Reference" linkID="567939"&gt;567939&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="567818"&gt;567818&lt;/ulink&gt;]. OPT-80 had a half-life of 0.94 to 2.77 h based on plasma concentration data from the 450-mg dose [&lt;ulink linkType="Reference" linkID="567939"&gt;567939&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;OPT-80 demonstrated antibacterial activity in further phase Ib and IIa clinical trials. In the phase Ib trial, OPT-80 was administered orally to 24 healthy individuals at doses of 150, 300 or 450 mg/day for 10 days. A phase IIa study involved 45 patients with CDAD receiving OPT-80 (50, 100 or 200 mg) orally every 12 h for 10 days. In both clinical trials, plasma concentrations were &amp;lt;/= 5 ng/ml across the dose range. In individuals receiving the highest dose in both studies, the drug was present in feces at concentrations &amp;gt; 10,000-fold higher than the MIC90 value of OPT-80 for C difficile [&lt;ulink linkType="Reference" linkID="643261"&gt;643261&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Two phase I clinical trials confirmed the safety and favorable pharmacokinetic parameters of OPT-80 administered orally as single doses of 200 to 450 mg [&lt;ulink linkType="Reference" linkID="567818"&gt;567818&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="567939"&gt;567939&lt;/ulink&gt;], or as ten daily doses of 100 to 450 mg [&lt;ulink linkType="Reference" linkID="643261"&gt;643261&lt;/ulink&gt;]. There was minimal absorption of the drug from the gut as reflected by very low plasma levels (often below the limits of quantification) and high concentrations in feces. Results were consistent with the therapeutic indication of OPT-80 for local antibacterial effects in the GI tract [&lt;ulink linkType="Reference" linkID="567818"&gt;567818&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="567939"&gt;567939&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="641458"&gt;641458&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="641815"&gt;641815&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In an open-label, phase IIa clinical trial involving 45 adults with CDAD randomized to receive 50, 100 or 200 mg of OPT-80 orally every 12 h for 10 days, 41 patients (91%) were cured, with the treatment of 2 patients in each of the two lower dose groups being changed to conventional therapy. Among the 41 patients successfully treated initially, only 2 (1 in each of the low- and high-dose groups) had recurrence of symptoms within the 6-week follow-up period [&lt;ulink linkType="Reference" linkID="643261"&gt;643261&lt;/ulink&gt;]. The researchers noted a trend in median time-to-cessation of diarrhea (5.5, 3.5 and 3.0 days for the 50-, 100- and 200-mg dose groups, respectively), suggesting that higher doses were more efficacious [&lt;ulink linkType="Reference" linkID="643261"&gt;643261&lt;/ulink&gt;]. In 32 patients, apparently a subset of this study, fecal C difficile counts dropped from a mean of 6.8 log10 CFU/g at study entry to &amp;lt; 2 log10 CFU/g at day 10 in all patients except one. A similar result was obtained with &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;. OPT-80 treatment caused no significant reduction in levels of Bacteroides organisms native to the gut [&lt;ulink linkType="Reference" linkID="732696"&gt;732696&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;The FDA approved protocols for phase III clinical trials, which commenced in early 2006 at centers in the US, Canada and Europe [&lt;ulink linkType="Reference" linkID="648913"&gt;648913&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="741137"&gt;741137&lt;/ulink&gt;]. These trials were to be conducted along with further phase II trials, with an expected completion date of March 2008. The clinical trials would consist of randomized, double-blind comparisons of OPT-80 and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; for the treatment of CDAD, with the cure rate at the end of therapy and the rate of recurrence as primary and secondary outcomes, respectively [&lt;ulink linkType="Reference" linkID="741137"&gt;741137&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;In a phase I, placebo-controlled study in 16 individuals administered oral OPT-80 at doses of 100 to 450 mg, five adverse events were observed, but were not considered to be treatment-related. There were no clinically significant abnormalities in hemodynamic or ECG data [&lt;ulink linkType="Reference" linkID="567818"&gt;567818&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="567939"&gt;567939&lt;/ulink&gt;]. In a phase Ib clinical trial, OPT-80 (150 to 450 mg/day po) administered to healthy individuals for 10 days was well tolerated, with no drug-related adverse events [&lt;ulink linkType="Reference" linkID="641815"&gt;641815&lt;/ulink&gt;]. Similarly, in the phase IIa study conducted concurrently, adverse events were considered unrelated to the drug [&lt;ulink linkType="Reference" linkID="643261"&gt;643261&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;OPT-80 was first claimed as an antibacterial agent (as lipiarmycin A3) by &lt;ulink linkType="Company" linkID="25218"&gt;Hoechst Marion Roussel&lt;/ulink&gt; in &lt;ulink linkType="Patent" linkID="IN260077"&gt;US-03978211&lt;/ulink&gt;. The same compound was subsequently claimed (as &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt;) by &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt; in &lt;ulink linkType="Patent" linkID="IN1479803"&gt;US-04918174&lt;/ulink&gt;, also as an antibacterial agent. &lt;ulink linkType="Patent" linkID="IN260077"&gt;US-03978211&lt;/ulink&gt; expired in August 1993. &lt;ulink linkType="Patent" linkID="IN1479803"&gt;US-04918174&lt;/ulink&gt; is due to expire in April 2007.&lt;/para&gt;&lt;para&gt;Optimer's first patent application relating to OPT-80 was &lt;ulink linkType="Patent" linkID="PA2888739"&gt;WO-2004014295&lt;/ulink&gt;, which claims methods for its preparation, and states that lipiarmycin A3 and &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; are the same compound. Subsequently, Optimer has filed a new use application, &lt;ulink linkType="Patent" linkID="PA3064211"&gt;WO-2005112990&lt;/ulink&gt;, claiming potential for the treatment of Staphylococcus (including multi-resistant strains such as methicillin-resistant S aureus [MRSA]) and Enterococcus spp. &lt;ulink linkType="Patent" linkID="PA3223602"&gt;WO-2006085838&lt;/ulink&gt; claims a composition of 70 to 100% tiacumicin A to F and 0 to 30% &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt;-related compounds (eg, lipiarmycin A4 or C(19) ketone), with greater activity against C difficile, S aureus, Enterococcus faecalis and Enterococcus faecium than &lt;ulink linkType="Drug" linkID="4553"&gt;tiacumicin B&lt;/ulink&gt; compounds alone.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;CDAD is a serious public health problem in both clinical and economic terms. Furthermore, recent data indicate that the epidemiology of CDAD may be changing and the problem is increasing in magnitude following the emergence and spread of an epidemic strain of C difficile, which produces disease characterized by increased morbidity and mortality. This strain has been reported from Canada, the US and parts of Europe, including the UK and the Netherlands [&lt;ulink linkType="Reference" linkID="732073"&gt;732073&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Currently, metronidazole and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; are recommended for the treatment of severe CDAD, but these agents are not ideal because many patients experience recurrence of infection, as well as side effects and resistance. Based on the available data, OPT-80 appears promising as a potential treatment of CDAD. OPT-80 demonstrated in vitro activity against strains of C difficile, although it is not clear if its activity has specifically been assessed against the epidemic strain of C difficile reported from Canada and other parts of the world. Additionally, good bioavailability of OPT-80 in the lower intestine (based on assays of fecal concentration) and lack of activity against Gram-negative rods (which might spare the normal microflora of the intestine) both suggest the usefulness of OPT-80 in the treatment of CDAD. The potential therapeutic value of OPT-80 was recognized by the FDA, who granted it Fast Track status for the treatment of CDAD in November 2004 [&lt;ulink linkType="Reference" linkID="568699"&gt;568699&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="648913"&gt;648913&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Preliminary data from a phase II clinical trial are particularly encouraging in that &amp;lt; 5% of CDAD patients treated with OPT-80 had recurrences within a 6-week follow-up period [&lt;ulink linkType="Reference" linkID="641815"&gt;641815&lt;/ulink&gt;]. This result contrasts favorably with current agents. However, the number of patients in the clinical trial was only moderate (n = 41) and further data are needed to determine whether these initial findings are reproducible. Further phase IIb/III clinical trials of OPT-80 in CDAD were scheduled to commence in early 2006, with an expected completion date of March 2008. These clinical trials would comprise randomized, double-blind comparisons of OPT-80 with &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; for the treatment of CDAD, with the cure rate at the end of therapy and the rate of recurrence as the primary and secondary endpoints for evaluation, respectively [&lt;ulink linkType="Reference" linkID="741137"&gt;741137&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An important factor that impacts on the clinical usefulness and longevity of new antibiotics is the emergence of resistance. Preclinical laboratory studies indicate that spontaneous resistance to OPT-80 due to mutation does not emerge readily [&lt;ulink linkType="Reference" linkID="568660"&gt;568660&lt;/ulink&gt;]. Similar preclinical findings have been reported for other licensed antibiotics, but widespread clinical use was followed by the emergence of resistant clinical isolates. However, in the case of OPT-80, fecal concentrations in phase II clinical trials exceeded the MIC90 concentration of OPT-80 for C difficile by a factor of 10,000, suggesting that resistance may not readily arise in patients because mutations conferring low-level or partial resistance would not survive. In the absence of available data on the mode of action of OPT-80, it is difficult to estimate the likelihood of mutants with high-level resistance arising. Nonetheless, OPT-80 has considerable potential as a new treatment option for CDAD.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073663" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-19T00:00:00.000Z</StatusDate><Source id="1383731" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><Source id="1444818" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><Source id="1450511" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-05T00:00:00.000Z</StatusDate><Source id="1699989" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-24T00:00:00.000Z</StatusDate><Source id="1491823" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-24T00:00:00.000Z</StatusDate><Source id="1491823" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-07T00:00:00.000Z</StatusDate><Source id="1298462" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><Source id="1358233" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-05T00:00:00.000Z</StatusDate><Source id="1699989" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-14T00:00:00.000Z</StatusDate><Source id="1410754" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-19T00:00:00.000Z</StatusDate><Source id="1352724" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-05-01T00:00:00.000Z</StatusDate><Source id="1354560" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-24T00:00:00.000Z</StatusDate><Source id="1491823" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XT">Caribbean Islands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-18T00:00:00.000Z</StatusDate><Source id="1393712" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XF">Central America</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-18T00:00:00.000Z</StatusDate><Source id="1393712" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-05T00:00:00.000Z</StatusDate><Source id="1460145" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-18T00:00:00.000Z</StatusDate><Source id="1393712" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-18T00:00:00.000Z</StatusDate><Source id="1393712" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XE">South America</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-18T00:00:00.000Z</StatusDate><Source id="1393712" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-18T00:00:00.000Z</StatusDate><Source id="1393712" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-24T00:00:00.000Z</StatusDate><Source id="1491823" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1481">Enterococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-24T00:00:00.000Z</StatusDate><Source id="1491823" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28968">Par Pharmaceutical Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-02-27T00:00:00.000Z</StatusDate><Source id="768860" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-05T00:00:00.000Z</StatusDate><Source id="1699989" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-05T00:00:00.000Z</StatusDate><Source id="1699989" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-04-30T00:00:00.000Z</StatusDate><Source id="1073393" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-04-30T00:00:00.000Z</StatusDate><Source id="1073393" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-29T00:00:00.000Z</StatusDate><Source id="1119727" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-07T00:00:00.000Z</StatusDate><Source id="1166261" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-12T00:00:00.000Z</StatusDate><Source id="1247655" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-05T00:00:00.000Z</StatusDate><Source id="1306423" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-03T00:00:00.000Z</StatusDate><Source id="1236034" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-03T00:00:00.000Z</StatusDate><Source id="1236034" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-05T00:00:00.000Z</StatusDate><Source id="1352724" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-22T00:00:00.000Z</StatusDate><Source id="1358233" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-29T00:00:00.000Z</StatusDate><Source id="1275897" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-19T00:00:00.000Z</StatusDate><Source id="1302254" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-19T00:00:00.000Z</StatusDate><Source id="1302254" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="XT">Caribbean Islands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-03T00:00:00.000Z</StatusDate><Source id="1346318" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-03T00:00:00.000Z</StatusDate><Source id="1346318" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-03T00:00:00.000Z</StatusDate><Source id="1346318" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-03T00:00:00.000Z</StatusDate><Source id="1346318" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-03T00:00:00.000Z</StatusDate><Source id="1346318" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1481">Enterococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-10-11T00:00:00.000Z</StatusDate><Source id="467209" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1313325" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1313325" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1313325" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1313325" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1313325" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-05T00:00:00.000Z</StatusDate><Source id="1306423" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-18T00:00:00.000Z</StatusDate><Source id="1208229" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-18T00:00:00.000Z</StatusDate><Source id="1208229" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1313325" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1490734" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1490734" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-01T00:00:00.000Z</StatusDate><Source id="1365353" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1044298">Specialised Therapeutics Australia Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-04-26T00:00:00.000Z</StatusDate><Source id="1410754" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1493254" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1493254" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-20T00:00:00.000Z</StatusDate><Source id="1493254" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-20T00:00:00.000Z</StatusDate><Source id="1493254" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-05T00:00:00.000Z</StatusDate><Source id="1699989" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089119">OBI Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-05T00:00:00.000Z</StatusDate><Source id="1699989" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-03T00:00:00.000Z</StatusDate><Source id="1521014" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-31T00:00:00.000Z</StatusDate><Source id="1949611" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-02T00:00:00.000Z</StatusDate><Source id="2050804" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-10-18T00:00:00.000Z</StatusDate><Source id="465351" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-28T00:00:00.000Z</StatusDate><Source id="546830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-11-03T00:00:00.000Z</StatusDate><Source id="568699" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28968">Par Pharmaceutical Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-05-03T00:00:00.000Z</StatusDate><Source id="598998" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28968">Par Pharmaceutical Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-13T00:00:00.000Z</StatusDate><Source id="741137" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-13T00:00:00.000Z</StatusDate><Source id="1073393" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-04-30T00:00:00.000Z</StatusDate><Source id="1073393" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-21T00:00:00.000Z</StatusDate><Source id="1133053" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-13T00:00:00.000Z</StatusDate><Source id="741137" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-27T00:00:00.000Z</StatusDate><Source id="1195908" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29549">Optimer Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-27T00:00:00.000Z</StatusDate><Source id="1195908" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="18077">Merck &amp; Co Inc</OwnerCompany><Country id="US">US</Country><Indication id="995">Clostridium difficile infection</Indication><AwardedIndication>Treatment of Clostridium difficile-associated diarrhea</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-11-03T00:00:00.000Z</MileStoneDate><Source id="568699" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29549">Optimer Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="995">Clostridium difficile infection</Indication><AwardedIndication>Treatment of pediatric Clostridium difficile infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-13T00:00:00.000Z</MileStoneDate><Source id="1175894" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="29549">Optimer Pharmaceuticals Inc</OwnerCompany><Country id="CA">Canada</Country><Indication id="995">Clostridium difficile infection</Indication><AwardedIndication>Treatment of Clostridium difficile infection (CDI), also known asClostridium difficile-associated diarrhea (CDAD)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-03T00:00:00.000Z</MileStoneDate><Source id="1236034" type="PR"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1089119">OBI Pharma Inc</OwnerCompany><Country id="TW">Taiwan</Country><Indication id="995">Clostridium difficile infection</Indication><AwardedIndication>Treatment of Clostridium difficile associated diarrhea (CDAD)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</MileStoneDate><Source id="1236034" type="PR"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="29549">Optimer Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="995">Clostridium difficile infection</Indication><AwardedIndication>Treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-24T00:00:00.000Z</MileStoneDate><Source id="1162863" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00590"><Name>Cytochrome P450 reductase</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-01699"><Name>RNA polymerase</Name><SwissprotNumbers><Swissprot>P20430</Swissprot><Swissprot>P27176</Swissprot><Swissprot>P27327</Swissprot><Swissprot>P37987</Swissprot><Swissprot>P09498</Swissprot><Swissprot>P09674</Swissprot><Swissprot>P21615</Swissprot><Swissprot>P22958</Swissprot><Swissprot>Q992J0</Swissprot><Swissprot>Q9QAZ8</Swissprot><Swissprot>Q96631</Swissprot><Swissprot>P17699</Swissprot><Swissprot>P11640</Swissprot><Swissprot>Q98745</Swissprot><Swissprot>P54891</Swissprot><Swissprot>P27738</Swissprot><Swissprot>P29045</Swissprot><Swissprot>P30738</Swissprot><Swissprot>Q66929</Swissprot><Swissprot>P90211</Swissprot><Swissprot>Q04575</Swissprot><Swissprot>Q02119</Swissprot><Swissprot>P17468</Swissprot><Swissprot>P31843</Swissprot><Swissprot>P29044</Swissprot><Swissprot>Q993M1</Swissprot><Swissprot>P07940</Swissprot><Swissprot>P14240</Swissprot><Swissprot>P89676</Swissprot><Swissprot>Q9DIC5</Swissprot><Swissprot>P15187</Swissprot><Swissprot>P27153</Swissprot><Swissprot>P28897</Swissprot><Swissprot>P29154</Swissprot><Swissprot>P20470</Swissprot><Swissprot>P27316</Swissprot><Swissprot>P27328</Swissprot><Swissprot>P00585</Swissprot><Swissprot>P52639</Swissprot><Swissprot>P29098</Swissprot><Swissprot>P09395</Swissprot><Swissprot>Q9YQ08</Swissprot><Swissprot>P37800</Swissprot><Swissprot>Q07630</Swissprot><Swissprot>P14241</Swissprot><Swissprot>P17459</Swissprot><Swissprot>P17520</Swissprot><Swissprot>P26190</Swissprot><Swissprot>P89659</Swissprot><Swissprot>O70695</Swissprot><Swissprot>Q84133</Swissprot><Swissprot>Q07518</Swissprot><Swissprot>Q9Q1T8</Swissprot><Swissprot>P18339</Swissprot><Swissprot>P15965</Swissprot><Swissprot>P03526</Swissprot><Swissprot>P03586</Swissprot><Swissprot>P22657</Swissprot><Swissprot>P22678</Swissprot><Swissprot>P22956</Swissprot><Swissprot>P69514</Swissprot><Swissprot>Q9IMM4</Swissprot><Swissprot>O93058</Swissprot><Swissprot>P23172</Swissprot><Swissprot>P28976</Swissprot><Swissprot>P20951</Swissprot><Swissprot>P22168</Swissprot><Swissprot>P22591</Swissprot><Swissprot>O41353</Swissprot><Swissprot>P27209</Swissprot><Swissprot>Q66431</Swissprot><Swissprot>P14647</Swissprot><Swissprot>P17460</Swissprot><Swissprot>P17779</Swissprot><Swissprot>P17965</Swissprot><Swissprot>P89202</Swissprot><Swissprot>Q9J7Z2</Swissprot><Swissprot>P35942</Swissprot><Swissprot>P21405</Swissprot><Swissprot>Q9YKD6</Swissprot><Swissprot>Q9YNA4</Swissprot><Swissprot>P33453</Swissprot><Swissprot>P69515</Swissprot><Swissprot>P04518</Swissprot><Swissprot>P27314</Swissprot><Swissprot>Q88920</Swissprot><Swissprot>P09505</Swissprot><Swissprot>Q66220</Swissprot><Swissprot>P34701</Swissprot><Swissprot>P13840</Swissprot><Swissprot>P15095</Swissprot><Swissprot>P15402</Swissprot><Swissprot>P89657</Swissprot><Swissprot>Q98631</Swissprot><Swissprot>P15962</Swissprot><Swissprot>P23456</Swissprot><Swissprot>P11623</Swissprot><Swissprot>P12002</Swissprot><Swissprot>P07393</Swissprot><Swissprot>P03587</Swissprot><Swissprot>P09507</Swissprot><Swissprot>P09675</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason></Reason><Description>Sales and market share updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=1604911" linkType="reference" linkID="1604911"&gt;1604911&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1604110" linkType="reference" linkID="1604110"&gt;1604110&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1052485">Optimer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1089119">OBI Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1089706">Endo International plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1157003">Specialised Therapeutics Asia Pte Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>3</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>2</CountAsPartnerInactive><CountTotal>10</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28769">Biocon Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30992">Patheon Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>1</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCc1c(c(c(c(c1Cl)O)Cl)O)C(=O)O[C@@H]2[C@H](O[C@H]([C@H]([C@H]2O)OC)OC/C/3=C\C=C\C[C@@H](/C(=C/[C@@H]([C@H](/C(=C/C(=C/C[C@H](OC3=O)[C@@H](C)O)/C)/C)O[C@H]4[C@H]([C@H]([C@@H](C(O4)(C)C)OC(=O)C(C)C)O)O)CC)/C)O)C</Smiles></StructureSmiles><Deals><Deal id="107854" title="Par to develop Optimer's OPT-80 in the US and Canada"></Deal><Deal id="121612" title="NIAID to award grants to Optimer Pharmaceuticals for development of antimicrobial and antibacterial agents"></Deal><Deal id="130660" title="Biocon to manufacture Optimer's fidaxomicin "></Deal><Deal id="133828" title="Astellas Pharma to develop and commercialize Optimer's fidaxomicin for clostridium difficile infection in Europe and certain countries in the Middle East, Africa, the CIS and Japan            "></Deal><Deal id="134435" title="Optimer and Cubist to copromote fidaxomicin in the US"></Deal><Deal id="140027" title="Specialised Therapeutics Australia to develop and market Optimer's fidaxomicin for clostridium difficile infection in Australia and New Zealand "></Deal><Deal id="142873" title="AstraZeneca to market Optimer's fidaxomicin in Latin America for Clostridium difficile infection   "></Deal><Deal id="145526" title="Patheon to manufacture and supply Optimer's fidaxomicin in North America, Europe and other countries"></Deal><Deal id="156551" title="Merck to develop and commercialize OBI Pharma's DIFICID against CDAD in Taiwan     "></Deal><Deal id="159531" title="OBI Pharma to commercialize Optimer Pharmaceuticals' fidaxomicin in Taiwan "></Deal><Deal id="236899" title="Cubist acquires Optimer Pharmaceuticals "></Deal></Deals><PatentFamilies><PatentFamily id="1125712" number="US-04918174" title="Tiacumicin compounds."></PatentFamily><PatentFamily id="1310592" number="WO-2008091518" title="Compositions of stable tiacumicins"></PatentFamily><PatentFamily id="1339645" number="WO-2006085838" title="18-Membered macrocycles and analogs thereof"></PatentFamily><PatentFamily id="1429391" number="US-03978211" title="Lipiarmycin and its preparation."></PatentFamily><PatentFamily id="1884199" number="WO-2005112990" title="Treatment of diseases associated with the use of antibiotics"></PatentFamily><PatentFamily id="2004336" number="WO-2011146624" title="Methods of treating recurring bacterial infection"></PatentFamily><PatentFamily id="2152249" number="WO-2011146621" title="Treatment of &lt;i&gt;Clostridium difficile&lt;/i&gt; infection in patients undergoing antibiotic therapy"></PatentFamily><PatentFamily id="2198533" number="WO-2009070779" title="Antibiotic macrocycle compounds and methods of manufacture and use thereof"></PatentFamily><PatentFamily id="2208165" number="WO-2007048059" title="Method of treating clostridium difficile-associated diarrhea"></PatentFamily><PatentFamily id="2431804" number="WO-2008091554" title="Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof"></PatentFamily><PatentFamily id="2478776" number="WO-2004014295" title="Tiacumicin production"></PatentFamily><PatentFamily id="2509597" number="CN-102993251" title="High-efficient liquid phase chromatography purification of tiacumicin B"></PatentFamily><PatentFamily id="2593007" number="WO-2013138748" title="Prevention of &lt;i&gt;Clostridium difficile&lt;/i&gt; infection in high risk patients"></PatentFamily><PatentFamily id="2605918" number="EP-02647719" title="Improved procedure for the production of tiacumicin B"></PatentFamily><PatentFamily id="2605923" number="EP-02647643" title="Procedure for the purification of tiacumicin b"></PatentFamily><PatentFamily id="2631280" number="WO-2013170142" title="Solid state forms of fidaxomicin and processes for preparation thereof"></PatentFamily><PatentFamily id="2639613" number="CN-103275153" title="One of non reach penicillin crystal and preparation method"></PatentFamily><PatentFamily id="2643874" number="CN-103320355" title="Actinoplanessp. strain and its use in preparation of fidaxomicin"></PatentFamily><PatentFamily id="2679467" number="WO-2014023616" title="Procedure for the production of tiacumicin B"></PatentFamily><PatentFamily id="2773672" number="WO-2014111254" title="Composition of tiacumicin compounds"></PatentFamily><PatentFamily id="2795961" number="WO-2014135891" title="Pharmaceutical compositions for rectal administration"></PatentFamily><PatentFamily id="2823297" number="WO-2014174528" title="An improved process for the preparation of fidaxomicin"></PatentFamily><PatentFamily id="2863153" number="WO-2016004848" title="Fidaxomicin purification method"></PatentFamily><PatentFamily id="2923524" number="WO-2015055107" title="Bacterial strain of actinoplanes sp. and application thereof"></PatentFamily><PatentFamily id="2935936" number="US-09387199" title="Compositions and methods for treating clostridium infection and preventing recurrence of infection"></PatentFamily><PatentFamily id="2937056" number="CN-104513286" title="A method for separating and purifying non - of method"></PatentFamily><PatentFamily id="2939231" number="US-20150141356" title="Treatment of &lt;i&gt;Clostridium difficile&lt;/i&gt; infection in high risk patients"></PatentFamily><PatentFamily id="2946181" number="CN-104561198" title="A fermentation production method of non-up"></PatentFamily><PatentFamily id="2948556" number="CN-104546672" title="A non-enteric-coated preparation"></PatentFamily><PatentFamily id="2948559" number="CN-104546666" title="Fidaxomicin solid dispersion and its preparation method"></PatentFamily><PatentFamily id="2961341" number="WO-2015091851" title="Process for the preparation of tiacumicin"></PatentFamily><PatentFamily id="3010186" number="WO-2015127955" title="A new polymorph of tiacumicin B and process for preparation thereof"></PatentFamily><PatentFamily id="3010220" number="WO-2015127956" title="Process for preparing novel forms of tiacumicin B"></PatentFamily><PatentFamily id="3035956" number="WO-2015140153" title="New polymorphs and new solid states of tiacumicin B"></PatentFamily><PatentFamily id="3047654" number="CN-104946708" title="A method for producing non-fermentation culture medium and fermentation method"></PatentFamily><PatentFamily id="3065651" number="WO-2015169451" title="Treatment regimen tiacumicin compound"></PatentFamily><PatentFamily id="3123745" number="WO-2016019371" title="Volatile organic compounds (VOCs) for the diagnosis of &lt;i&gt;Clostridium difficile&lt;/i&gt;-associated diarrhea (CDAD)"></PatentFamily><PatentFamily id="3131636" number="WO-2016024243" title="Fidaxomicin polymorphs and processes for their preparation"></PatentFamily><PatentFamily id="3197194" number="CN-105585602" title="Fidaxomicin compound"></PatentFamily><PatentFamily id="3218212" number="CN-105640973" title="Stable fidaxomicin medicine composition"></PatentFamily><PatentFamily id="3255281" number="CN-104418925" title="Claims a method for preparing high-purity non-reach"></PatentFamily><PatentFamily id="3507691" number="WO-2017005358" title="Novel dosage regimen tiacumicin compound"></PatentFamily><PatentFamily id="3683352" number="WO-2017100420" title="Biomarkers for predicting clostridium difficile infection treatment outcome"></PatentFamily><PatentFamily id="3824642" number="CN-107236686" title="Dactylosporangium aurantiacum and application in not reaching and controlling microorganism metabolite"></PatentFamily><PatentFamily id="4024912" number="CN-107898801" title="Composition containing rifampicin and lipiarmycin and application of composition"></PatentFamily><PatentFamily id="4288530" number="CN-108841769" title="Fidaxomicin genetically engineered bacterium and construction method and application thereof"></PatentFamily><PatentFamily id="442705" number="WO-2011044208" title="Antibiotic formulations providing reduced gastrointestinal side effects"></PatentFamily><PatentFamily id="751012" number="WO-2012106722" title="Treatment of bacterial infections"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>12</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>16</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>8</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="North China Pharmaceutical Group Corp (NCPC)" id="1005667"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang University" id="1014561"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Concord Biotech Ltd" id="1018960"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Hisun Pharmaceutical Co Ltd" id="1019688"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Brightgene Bio-Medical Technology Co Ltd" id="1025424"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xellia Pharmaceuticals AS" id="1056731"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dorfner Family Medicine" id="1061674"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Hankang Pharmaceutical Biotechnology" id="1065273"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Nanomicro Technology Company Limited" id="1075307"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing Qiantai Biological Pharmaceutical Co Ltd" id="1111533"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd" id="1176077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>12</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>12</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Virginia" id="20695"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Basilea Pharmaceutica International Ltd" id="28104"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fidia Group" id="29994"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>